Line thrombus – anticoagulation

Following ward round on 10 November, please find below some further reading on anticoagulation for patients with catheter-related thrombosis.

Please note that inclusion in this blog is not an endorsement of quality.

Please follow local protocols for drug doses.

To access full text you will need an NHS OpenAthens account. Please sign up here if you haven’t already got one.

KnowledgeShare is a current awareness tool which helps you deal with information overload, while ensuring that you receive high quality information on topics that are important to you. Take five minutes to fill in this form and we will send you regular updates on your chosen topic.

Guideline

Association of Anaesthetists guidelines: safe vascular access 2025 See especially the final part of the section on ‘coagulopathies, anticoagulation and catheter-related venous thrombosis’ on page 12 in the PDF

DynaMed

DynaMed (2026) Catheter-Related Thrombosis

See especially the following sections:

Catheter-Related Thrombosis > Overview and Recommendations > Management > Therapy of Established Catheter-Related Thrombosis

Catheter-Related Thrombosis > Management > Medications > Anticoagulants

Articles

1. Risk Factors for Catheter-Related Thrombosis

Authors: La Cava, Leyla; Giustivi, Davide; Bartoli, Arianna, et al
Publication Date: 2026
Journal: Journal of Clinical Medicine 15(10), pp.3932. doi: 10.3390/jcm15103932

Abstract: Background: Although guidelines emphasize proper insertion techniques and tip positioning, catheter-related thrombosis (CRT) remains a common and clinically significant complication of peripherally inserted central catheters (PICCs) and midline catheters (MCs). In this context, the use of pharmacological prophylaxis is still debated. This study aims to assess the incidence of CRT in patients receiving anticoagulant therapy (therapeutic or prophylactic) and antiplatelet therapy. Methods: This retrospective study was conducted at a tertiary care hospital and included adult patients from March 2021 to May 2023. Six potential confounders were analyzed: anticoagulation status (none, prophylaxis, therapeutic), antiplatelet therapy, tip position (PICCs vs. MCs), number of lumens, CRT risk factors, and drug infusion requiring central access. CRT was diagnosed in symptomatic patients using compression ultrasonography. Propensity score weighting and logistic regression were employed to estimate odds ratios (OR) and average treatment effects. Results: A total of 1431 patients were enrolled. PICCs and therapeutic anticoagulant therapy were highly protective against CRT (OR 0.068 [95% CI 0.013-0.2] and OR 0.007 [95% CI 0.001-0.046], respectively). Prophylactic anticoagulant therapy (OR 0.328 [95% CI 0.200-0.519]) and antiplatelet therapy (OR 0.342 [95% CI 0.182-0.595]) also showed protective effects. At the same time, neither the number of lumens, the presence of risk factors, nor the infusion of irritating drugs was independently associated with CRT. Conclusions: The use of anticoagulant drugs (both prophylactic and therapeutic), antiplatelet therapy, and PICC use significantly lowered the risk of CRT. The findings support personalized prevention strategies and underscore the need for a well-designed randomized controlled trial to validate these findings.

Access full text https://libkey.io/10.3390/jcm15103932

2. Treatment of catheter related thrombosis: A systematic review, meta-analysis, and national survey

Authors: Oomen, Laurens A.; van Diest, Janette; Lucas, Felice R. M., et al
Publication Date: 2026
Journal: Journal of Vascular Surgery.Venous and Lymphatic Disorders 14(2), pp.102359

Abstract: BACKGROUND: Catheter-related thrombosis (CRT) is a known complication of central venous catheters and peripherally inserted central catheters, yet optimal treatment remains uncertain. We conducted a systematic review and national survey to assess current CRT management strategies. METHODS: Following the PRISMA guidelines, we searched three databases through October 2024 for studies on CRT associated with central venous catheters or peripherally inserted central catheters. Meta-analyses and subgroup analyses were performed by anticoagulant type. A national survey among Dutch intensive care and hematology physicians explored current treatment practices. RESULTS: Of 4123 records screened, 34 observational studies were included, mostly involving patients with cancer. The venous thromboembolism recurrence rate per 100 patient-years was higher in patients with cancer (14.1; 95% confidence interval, 11.4- 17.4; I(2) = 35.1) vs patients without cancer (2.0; 95% confidence interval, 0.6-6.0; I(2) = 10.3; P = .0002). Recurrence was comparable between direct oral anticoagulants (DOACs) and low-molecular-weight heparin/vitamin K antagonists (LMWH/VKAs), at 11.0 vs 7.6 (P = .14). Major bleeding occurred in 10.5 vs 13.1 (P = .45), and clinically relevant nonmajor bleeding in 26.2 vs. 22.4 (P = .70), for DOACs vs LMWH/VKAs, respectively. All studies were observational, most at high risk of bias. Survey data showed LMWH was preferred for symptomatic CRT (50%), with treatment lasting 8 days to 6 months. In asymptomatic CRT, anticoagulant type and duration were left to physician discretion in 64% of cases. CONCLUSIONS: Treatment with LMWH/VKA or DOACs shows similarly low venous thromboembolism recurrence, although rates are higher in patients with cancer. Bleeding was substantial and comparable across therapies. Evidence is limited by observational bias. Survey data show that LMWH predominates for CRT, with variable duration. Well-designed randomized controlled trials are warranted.

Access full text https://libkey.io/10.1016/j.jvsv.2025.102359

3. Critical Review of International Clinical Practice Guidelines Recommendations for Prevention, Diagnosis, and Management of Central Venous Catheter Thrombosis

Authors: Rosson, Marco; D’Oria, Mario; Simion, Chiara, et al
Publication Date: 2026a
Journal: Thrombosis and Haemostasis 126(6), pp.553–567

Abstract: Central venous catheters (CVCs) are widely used in clinical practice for the administration of medications, parenteral nutrition, and hemodynamic monitoring. However, their use is associated with a significant risk of thrombosis, which can lead to serious complications, including catheter dysfunction, infection, and embolism. Numerous international clinical practice guidelines (CPGs) have been developed to address the prevention, diagnosis, and management of CVC-related thrombosis. This critical review aims to evaluate and compare the recommendations provided by these guidelines, highlighting areas of consensus, variation, and potential gaps. We systematically analyzed CPGs from major healthcare organizations, focusing on key aspects such as risk stratification, prophylactic strategies, diagnostic algorithms, and therapeutic interventions. Although most guidelines emphasize the importance of risk assessment and early intervention, there are notable discrepancies in recommendations regarding the use of anticoagulant prophylaxis, imaging modalities for diagnosis, and the duration of anticoagulation therapy. Additionally, the review explores the evidence underpinning these recommendations and identifies areas where robust clinical data are lacking. Our analysis underscores the need for harmonization across guidelines to ensure consistent and evidence-based care. Furthermore, we advocate for the development of multidisciplinary approaches to enhance decision-making and optimize clinical outcomes in this domain. By addressing the gaps and inconsistencies in current CPGs, this review seeks to provide a framework for improving the prevention, diagnosis, and management of CVC-related thrombosis, ultimately enhancing patient outcomes and reducing the healthcare burden.

Request full text https://libkey.io/10.1055/a-2649-9451

4. Utilizing evidence-based diagnosis and treatment for central venous thrombosis: closing the gaps where guidelines fail

Authors: Rosson, Marco; D’Oria, Mario; Simion, Chiara, et al
Publication Date: 2026b
Journal: Expert Review of Hematology, pp.1–12

Abstract: INTRODUCTION: Catheter-related thrombosis (CRT) is a frequent complication of central venous catheters and accounts for most upper extremity deep vein thrombosis events. Despite its increasing clinical burden, management remains poorly standardized because recommendations are largely extrapolated from general venous thromboembolism studies rather than CRT-specific evidence. AREAS COVERED: We performed a structured comparative review of major international, European, and North American guidelines, consensus documents, and position statements identified through PubMed, Ovid, and Scopus searches covering January 2016 to March 2026. Nineteen documents from vascular medicine, oncology, and vascular access societies were included. Recommendations on diagnostic strategies, imaging modalities, catheter management, anticoagulant selection, treatment duration, and invasive interventions were systematically compared. EXPERT OPINION: Considerable heterogeneity persists across recommendations. Ultrasound is consistently endorsed as the first-line imaging modality, whereas the role of clinical prediction scores and D-dimer remains uncertain because neither has been validated in CRT populations. Catheters should be preserved when functional, correctly positioned, and free from infection. Anticoagulation for at least 3 months is universally recommended, while invasive procedures should be reserved for selected patients with extensive thrombosis or life- or limb-threatening complications. Prospective studies are urgently needed to validate diagnostic algorithms, optimize anticoagulant strategies, and develop CRT-specific evidence-based pathways.

Access full text https://libkey.io/10.1080/17474086.2026.2755169

5. Catheter-related deep vein thrombosis: Where are we at and where are we going? Updates and ongoing unmet clinical needs

Authors: Girardi, Laura; Di Nisio, Marcello; Candeloro, Matteo, et al
Publication Date: 2025
Journal: European Journal of Clinical Investigation 55(1), pp.e14311

Abstract: BACKGROUND: Catheter-related thrombosis (CRT) is one of the major complications affecting patients with indwelling venous catheters, usually involving the upper extremity deep venous system. This condition can lead to potentially life-threatening complications such as pulmonary embolism and sepsis. The risk of developing CRT varies depending on type of catheters and patient characteristics. Despite advances in materials and technologies, the actual incidence of CRT is still considerable. Available evidence on CRT management remains controversial, and clinical guidelines base their recommendations on data from non-catheter related upper extremity or lower extremity deep venous thromboses. AIMS: This narrative review aims to describe the epidemiology of CRT, to review the available evidence on its management and to highlight the current unmet needs. METHODS: No formal search strategy was applied for the revision of the literature. The main sources of information used were Medline and guidelines from international societies. CONTENT: The management of CRT requires a careful balance between the risk of thrombus progression, recurrent events, and systemic embolization and the increased bleeding risk in often fragile patients. Open issues include the optimal management of the catheter and the type and duration of anticoagulant therapy. Direct oral anticoagulants are increasingly prescribed, representing an important alternative to the standard of care low molecular weight heparins in selected cases. The development of new anticoagulant drugs such as factors XI and XII inhibitors may offer further advantages in this context. CONCLUSIONS: The management of CRT is still challenging with constant need for updated evidence to support tailored approaches.

Access full text https://libkey.io/10.1111/eci.14311

6. Unveiling the complexities of catheter-related thrombosis: risk factors, preventive strategies, and management

Authors: King, Hannah L.; Padilla-Lazos, Thalia; Chitkara, Akshit, et al
Publication Date: 2025
Journal: Journal of Thrombosis and Thrombolysis 58(3), pp.443–457

Abstract: Catheter-related deep venous thrombosis (CR-DVT) is a common complication of central venous catheters, however optimal prophylactic and treatment strategies have yet to be fully defined. While the use of anticoagulation for CR-DVT prophylaxis is not routinely recommended, current available data offer heterogeneous results due to small sample size, non-uniform study design, and varying comorbid conditions. Available guidelines for the treatment of CR-DVT generally recommend a limited duration of anticoagulation after catheter removal. If ongoing use is required and the device remains functional, guidelines support anticoagulation throughout the time the catheter remains in place. It is worth acknowledging that data guiding these recommendations is largely derived from observational studies of upper extremity CR-DVT, along with randomized trials of anticoagulation in patients with lower extremity DVT. Therefore, large, randomized controlled trials are desperately needed to define optimal management, especially in patients who are at high risk for bleeding. This review explores the epidemiology and risk factors of CR-DVT, diagnostic, prophylactic and treatment strategies, guideline recommendations, and future advances in the field, including the introduction of novel anticoagulants. With current available evidence, we also conclude with an individualized approach to preventing and managing CR-DVT to assist clinicians who are faced with this common clinical scenario.

Access full text https://libkey.io/10.1007/s11239-025-03073-7

7. A Comprehensive Review of Catheter-Related Thrombosis

Authors: López-Rubio, Marina; Lago-Rodríguez, Marta-Olimpia; Ordieres-Ortega, Lucía, et al
Publication Date: 2024
Journal: Journal of Clinical Medicine 13(24), pp.7818. doi: 10.3390/jcm13247818

Abstract: Catheter-related thrombosis (CRT) is a frequent and potentially serious complication associated with the widespread use of intravascular devices such as central venous catheters, including peripherally inserted central catheters and implantable port systems, pacemakers or implantable cardioverter-defibrillators. Although CRT management has been informed by guidelines extrapolated from lower extremity deep vein thrombosis (DVT), unique challenges remain due to the distinct anatomical, pathophysiological, and clinical characteristics of upper extremity DVT. Risk factors for CRT are multifactorial, encompassing patient-related characteristics such as cancer, prior venous thromboembolism, and infection, as well as catheter-specific factors like device type, lumens, and insertion site. The diagnosis of CRT relies primarily on ultrasonography; however, computed tomography angiography and magnetic resonance imaging play a complementary role, particularly in anatomically challenging cases or when complications such as pulmonary embolism or superior vena cava syndrome are suspected. Treatment strategies for CRT include anticoagulation, catheter removal when feasible, and, in select cases, local thrombolysis or catheter-directed interventions. Anticoagulation remains the cornerstone of therapy, with direct oral anticoagulants increasingly favored due to their safety profile and efficacy. This article provides a detailed review of CRT, focusing on clinical features, diagnostic methods, and treatment strategies while addressing specific challenges in managing pacemaker and hemodialysis catheter-related thrombosis.

Access full text https://libkey.io/10.3390/jcm13247818

Posted in Ward Round Update | Leave a comment

Hyponatraemia

Please find below some further reading on hyponatraemia.

Please note that inclusion in this blog is not an endorsement of quality.

Please follow local protocols for drug doses.

To access full text you will need an NHS OpenAthens account. Please sign up here if you haven’t already got one.

KnowledgeShare is a current awareness tool which helps you deal with information overload, while ensuring that you receive high quality information on topics that are important to you. Take five minutes to fill in this form and we will send you regular updates on your chosen topic.

DynaMed and BMJ Best Practice

DynaMed (2026) Hyponatremia in Adults – Approach to the Patient > Management See also the section on Management of Overcorrection of Hyponatremia

DynaMed (2024) Postoperative Electrolyte Abnormalities in Adults > Hyponatremia

BMJ Best Practice (2026) Hyponatraemia

Articles

1. Proactive desmopressin for the prevention of serum sodium overcorrection in moderate-to-severe hyponatremia: a systematic review and meta-analysis

Authors: Lins, Paulo Ricardo Gessolo; Uvinha, Fernando; Passos, Felipe S., et al
Publication Date: 2026
Journal: BMC Nephrology 27(1), pp.494. doi: 10.1186/s12882–0

Abstract: BACKGROUND: Hyponatremia is the most common electrolyte disorder in hospitalized patients and is associated with increased morbidity and mortality. Correction is challenging because rapid increases in serum sodium may lead to osmotic demyelination. Desmopressin is used to stabilize free-water excretion, but the effectiveness of proactive administration has not been systematically evaluated. METHODS: We searched PubMed-MEDLINE, Embase, and the Cochrane Library registries from inception through February 2026. We included studies enrolling adults with moderate-to-severe hyponatremia receiving standard therapy that compared proactive desmopressin with non-proactive usual-care strategies. Two reviewers independently extracted data and assessed risk of bias using ROBINS-I v2 and RoB 2. The primary outcome was serum sodium overcorrection using study-defined thresholds. Secondary outcomes included osmotic demyelination syndrome (ODS), mortality, hospital length of stay, worsening hyponatremia, and total hypertonic saline volume infused. RESULTS: Six studies including 1,881 patients were included, of whom 168 received proactive desmopressin. Proactive desmopressin was associated with significantly lower odds of overcorrection compared with non-proactive usual-care strategies (OR, 0.29; 95% CI, 0.19-0.45; p  8, >10, and > 12 mEq/L at 24 h and > 18 mEq/L at 48 h. Cases of ODS were rare and did not differ significantly between groups. Mortality, hospital length of stay, total hypertonic saline volume infused, and worsening hyponatremia also did not differ significantly between groups. CONCLUSIONS: In adults with moderate-to-severe hyponatremia receiving standard therapy, proactive desmopressin was associated with a lower risk of overcorrection. This reduction was not accompanied by clear differences in ODS, worsening hyponatremia, or mortality. Further prospective randomized studies are needed to better define the optimal timing, dosing, and patient selection for this strategy. PROSPERO: CRD420251043907 CLINICAL TRIAL NUMBER: Not applicable.

Access full text https://libkey.io/10.1186/s12882-026-05128-0

2. Hyponatremia: Evolving diagnostics and emerging therapeutics in clinical practice

Authors: Martínez-Sánchez, Froylan David; Gutierrez-Rosas, Luis Enrique; Barranco-Hernandez, Luis Hernan, et al
Publication Date: 2026
Journal: World Journal of Nephrology 15(1), pp.115252

Abstract: Hyponatremia remains the most common electrolyte disorder in clinical practice, with a wide range of causes ranging from endocrine dysregulation to iatrogenic causes. Recent developments in point-of-care ultrasonography, vasopressin physiology, and osmoregulation have transformed diagnostics by emphasizing accuracy above purely clinical judgment. Although traditional management based on fluid restriction and hypertonic solutions remain the cornerstone of treatment, a careful and cautious monitoring is required to avoid osmotic demyelination and overcorrection. The Furst equation, a validated predictor of response to fluid restriction, should be integrated into routine practice, together with objective tools such as point-of-care ultrasonography, to improve the accuracy of volume assessment and guide more precise therapeutic decisions. Likewise, different therapeutic options have been studied for non-responders to fluid restriction, including urea, desmopressin, and selective vasopressin receptor antagonists (vaptans), showing promising results. Ongoing developments in artificial intelligence and laboratory-based decision support tools are expected to improve personalized management and predictive accuracy, potentially reconciling the disparity between evidence and clinical practice.

Access full text https://libkey.io/10.5527/wjn.v15.i1.115252

3. The treatment of acute symptomatic hyponatraemia in the hospital setting

Authors: Prince, Rebecca; Chifu, Irina and Arshad, Muhammad Fahad
Publication Date: 2026
Journal: Best Practice & Research.Clinical Endocrinology & Metabolism 40(1), pp.102079

Abstract: Acute symptomatic hyponatraemia results in potentially fatal cerebral oedema, whereas overly rapid correction of hyponatraemia can cause osmotic demyelination syndrome (ODS) with permanent neurological damage. To balance these two risks, we recommend a limited rapid increase of serum sodium level by at least 5 mmol/l by administration of fixed bolus(es) of hypertonic saline (HTS) to reverse symptoms of cerebral oedema, while limiting total increase to 8-10 mmol/l in the first 24 h, and each subsequent 24 h period. Neurological status, urine output, and biochemistry should be carefully monitored. Desmopressin and/or intravenous dextrose are recommended to reverse or prevent overly rapid correction. Interventional trials focused on optimal HTS volume, best approaches for prevention and treatment of overly rapid correction, and their clinical outcomes are needed for strong evidence-based recommendations.

Request full text https://libkey.io/10.1016/j.beem.2025.102079



4. Hyponatremia

Authors: Rout, Preeti and Afzal, Muriam
Publication Date: 2026
Journal: StatPearls

Abstract: A crucial development that enabled animals to migrate from aquatic to terrestrial environments was the ability to regulate and conserve water and salt during periods of excess and scarcity. However, when this equilibrium is disturbed, hyponatremia can result. Hyponatremia is the most common electrolyte abnormality among hospitalized patients; therefore, understanding its causes is vitally important to patient care. This condition is usually defined as a serum sodium concentration less than 135 mEq/L, although the threshold may vary slightly depending on the laboratory’s reference range. Hyponatremia is caused by an excess of total body water compared to total body sodium. Sodium and water balance depend on a complex interplay between volume status, antidiuretic hormone, kidney function, cardiac function, natriuretic peptides, and other hormones. Hyponatremia represents an imbalance between total body water and total body solutes, in which total body water exceeds total body solutes. Total body water comprises 2 main compartments: extracellular fluid, which accounts for one-third, and intracellular fluid, which accounts for the remaining two-thirds. Sodium is the primary solute of extracellular fluid, and potassium is the primary solute of intracellular fluid. Hyponatremia can be classified as follows: Mild: 130 to 135 mEq/L. Moderate: 125 to 130 mEq/L. Severe: < 125 mEq/L . Patients with hyponatremia are classified into 3 main categories based on volume status: hypovolemic, euvolemic, and hypervolemic. In addition, patients can be categorized by tonicity as hypotonic, eutonic, or hypertonic. Tonicity is defined as the amount of effective osmoles that cannot cross the cellular membrane from the extracellular to the intracellular space and therefore influence the movement of water across cell membranes. Tonicity differs from serum osmolality, which includes all solutes and is calculated as follows: Serum Osmolality = 2 × (Na) + (Glucose)/18 + (Blood Urea Nitrogen)/2.8, Osmolality is dependent on the properties of the solution and independent of movement across a membrane. Tonicity excludes urea because it freely crosses cell membranes. Tonicity can also be considered a measurement of effective osmoles and is calculated as follows: Tonicity = 2 x (Na) + (Glucose)/18, In normoglycemia, glucose can be excluded because its contribution to tonicity is minimal (5 to 10 mOsm/kg). The reference range for tonicity is 285 to 295 mOsm/kg. Hypertonicity is greater than 295 mOsm/kg, whereas hypotonicity is less than 285 mOsm/kg. Most patients with hyponatremia have hypotonic hyponatremia. Exceptions include patients with hyperglycemia, patients who received mannitol or immunoglobulins, and patients with pseudohyponatremia. Understanding and treating hyponatremia is important because findings from studies have shown that even mild hyponatremia increases morbidity and mortality, particularly in older adults.

Access full text https://www.ncbi.nlm.nih.gov/books/NBK470386/

5. Correction Rates and Clinical Outcomes in Hospitalized Adults With Severe Hyponatremia: A Systematic Review and Meta-Analysis

Authors: Ayus, Juan Carlos; Moritz, Michael L.; Fuentes, Nora Angélica, et al
Publication Date: 2025
Journal: JAMA Internal Medicine 185(1), pp.38–51

Abstract: IMPORTANCE: Hyponatremia treatment guidelines recommend limiting the correction of severe hyponatremia during the first 24 hours to prevent osmotic demyelination syndrome (ODS). Recent evidence suggests that slower rates of correction are associated with increased mortality. OBJECTIVE: To evaluate the association of sodium correction rates with mortality among hospitalized adults with severe hyponatremia. DATA SOURCES: We searched MEDLINE, Embase, the Cochrane Library, LILACS, Web of Science, CINAHL, and international congress proceedings for studies published between January 2013 and October 2023. STUDY SELECTION: Comparative studies assessing rapid (≥8-10 mEq/L per 24 hours) vs slow (<8 or 6-10 mEq/L per 24 hours) and very slow (<4-6 mEq/L per 24 hours) correction of severe hyponatremia (serum sodium <120 mEq/L or <125 mEq/L plus severe symptoms) in hospitalized patients. DATA EXTRACTION AND SYNTHESIS: Pairs of reviewers (N.A.F., J.R.M., J.M.A., A.C.) independently reviewed studies, extracted data, and assessed each included study’s risk of bias using ROBINS-I. Cochrane methods, PRISMA reporting guidelines, and the GRADE (Grading of Recommendations Assessment, Development and Evaluation) approach to rate the certainty of evidence were followed. Data were pooled using a random-effects model. MAIN OUTCOMES AND MEASURES: Primary outcomes were in-hospital and 30-day mortality, and secondary outcomes were hospital length of stay (LOS) and ODS. RESULTS: Sixteen cohort studies involving a total of 11 811 patients with severe hyponatremia were included (mean [SD] age, 68.22 [6.88] years; 56.7% female across 15 studies reporting sex). Moderate-certainty evidence showed that rapid correction was associated with 32 (odds ratio, 0.67; 95% CI, 0.55-0.82) and 221 (odds ratio, 0.29; 95% CI, 0.11-0.79) fewer in-hospital deaths per 1000 treated patients compared with slow and very slow correction, respectively. Low-certainty evidence suggested that rapid correction was associated with 61 (risk ratio, 0.55; 95% CI, 0.45-0.67) and 134 (risk ratio, 0.35; 95% CI, 0.28-0.44) fewer deaths per 1000 treated patients at 30 days and with a reduction in LOS of 1.20 (95% CI, 0.51-1.89) and 3.09 (95% CI, 1.21-4.94) days, compared with slow and very slow correction, respectively. Rapid correction was not associated with a statistically significant increased risk of ODS. CONCLUSIONS AND RELEVANCE: In this systematic review and meta-analysis, slow correction and very slow correction of severe hyponatremia were associated with an increased risk of mortality and hospital LOS compared to rapid correction.

Access full text https://libkey.io/10.1001/jamainternmed.2024.5981

6. Severe symptomatic hyponatremia in Europe: insights into current clinical practice

Authors: Beck, Julia; Arshad, Muhammad Fahad; Iqbal, Ahmed, et al
Publication Date: 2025
Journal: European Journal of Endocrinology 192(6), pp.754–762

Abstract: INTRODUCTION: For the treatment of severe symptomatic hyponatremia, the European Society of Endocrinology (ESE) guidelines (2014) recommend a bolus-wise strategy using hypertonic saline (HTS). However, there are recent controversies regarding the risk of overcorrection and osmotic demyelination syndrome (ODS), leading to significant heterogeneity in practice. The aim of this survey was to evaluate clinical practices and perspectives of endocrinologists across Europe in managing severe symptomatic hyponatremia. METHODS: A web-based anonymous cross-sectional survey (REDCap®), endorsed by ESE, was disseminated from 06, 2024 to 02, 2025. Data were analyzed using R-Studio. RESULTS: A total of 662 responses were received. After excluding incomplete and non-European responses, 439 responses from 36 countries were analyzed. Most responses were received from university hospitals (68.6%) and senior clinicians (68.1%). Thirty-one percent of clinicians had experience using both bolus and continuous infusions in managing severe symptomatic hyponatremia, while sole bolus or continuous infusion therapy was preferred by 32% and 23%, respectively. Preferred bolus dosage and strength were 3% 100 mL (28%) and 3% 150 mL (19%), while 5% preferred a weight-based dosage. Most (84%) clinicians preferred one bolus infusion followed by a blood test before repeating a second. Thirty-four percent of respondents had encountered ≥1patient with suspected or confirmed ODS in their practice, with 55% reported ODS being associated with sodium overcorrection. DISCUSSION: This is the first European survey on the management of severe symptomatic hyponatremia, offering valuable insights into real-life clinical practice. Our findings highlight ongoing uncertainties in treatment strategies and underscore the need for future research and evidence-based review of the ESE guidelines.

Access full text https://libkey.io/10.1093/ejendo/lvaf115

7. Incidence and risk factors of hyponatremia after transsphenoidal surgery: a systematic meta-analysis

Authors: Webb, Kevin L.; Reilly, Charles E. 3rd; Hinkle, Mickayla L., et al
Publication Date: 2025
Journal: Neurosurgical Review 48(1), pp.630–8

Abstract: The transsphenoidal approach to sellar lesions is a mainstay technique in modern neurosurgical treatment of pituitary adenomas. One prominent complication following transsphenoidal surgery is the development of postoperative hyponatremia, frequently necessitating additional medical management and hospital readmission. However, the precise incidence and risk factors of postoperative hyponatremia remain unclear in the current literature. We conducted a systematic meta-analysis of 104 studies (31,676 patients) to clarify the incidence of postoperative hyponatremia and associated hospital readmission, as well as to summarize conflicting findings regarding significant risk factors of postoperative hyponatremia. The overall incidence of postoperative hyponatremia following transsphenoidal surgery was 13.3% [95% Confidence Interval (CI): 11.8-14.7%; 96 studies]. The rate of hospital readmission due to postoperative hyponatremia was 3.3% [95% CI: 2.7-3.9%; 33 studies]. Factors such as infundibular stalk deviation angle, plasma copeptin level, and Knosp grades served as more reliable predictors of postoperative hyponatremia. In contrast, conventional demographic and surgical parameters such as patient age, body mass index, sex, and extent of resection were not consistently identified as significant predictive factors. Secondary analyses revealed that prophylactic fluid restriction significantly reduced the incidence of postoperative hyponatremia from ~ 13.1% to ~ 4.0% (Odds Ratio 3.39 [95% CI; 2.18-5.26, Z = 5.545, P < 0.001]. This meta-analysis establishes definitive ‘benchmarks’ for anticipated complications after transsphenoidal surgery while highlighting important factors such as prophylactic fluid restriction protocols as a key source of inter-study variability. In addition, this study summarizes the congruence of the predictive factors thought to be influential in leading to postoperative hyponatremia, highlighting key areas of (dis)agreement.

Request full text https://libkey.io/10.1007/s10143-025-03784-8

8. The risk of sodium overcorrections in severe hyponatremia and the utility of desmopressin: a large retrospective study

Authors: Lamarche, Florence; Ammann, Hélène; Dallaire, Gabriel, et al
Publication Date: 2024
Journal: Clinical Kidney Journal 18(2), pp.sfae386

Abstract: BACKGROUND: The suggested narrow rate of serum sodium (sNa) correction in hyponatremia can be difficult to respect, leading to overcorrections. Our ability to anticipate the rapidity of correction according to the mechanism of hyponatremia is uncertain. While desmopressin is often used to pause a rapid rise in sNa, its dose-related effect is also not well described. We studied the rate of hyponatremia overcorrections, its prediction and the utility of desmopressin in its management. METHODS: We retrospectively reviewed all cases of severe hyponatremia (sNa 9 mmol/L per day sustained over at least 24 h. RESULTS: After exclusions, we found 355 episodes of severe hyponatremia. Low, appropriate and inappropriate antidiuretic hormone (ADH)-defined mechanisms accounted for 17%, 24% and 29% of etiologies, respectively, with the remaining 25% secondary to diuretics and 5% of uncertain causes. First urinary sodium and osmolality were consistent with the final diagnosis in 73%. Significant overcorrections were seen in 45% and were frequent in the setting of low ADH. Desmopressin was given in 82 episodes, more often as a rescue than a preventive measure, with the subsequent sNa dropping by ≥5 mmol/L by 12 h in eight instances. The dose of desmopressin (≥2 µg versus 1 µg) and a higher volume of intravenous free-water coadministration resulted in a clinically meaningful greater reduction in sNa in the following 12 h. CONCLUSIONS: Overcorrections in severe hyponatremia are common, mainly when ADH is low. Initial urinary measurements anticipate this risk. Desmopressin effectively halted the rate of correction in a dose-dependent manner. Caution should be given when coadministrating water, which can significantly lower the sNa.

Access full text https://libkey.io/10.1093/ckj/sfae386

9. Intensive Care Management of Severe Hyponatraemia-An Observational Study

Authors: Roe, Thomas; Brown, Mark; Watson, Adam J. R., et al
Publication Date: 2024
Journal: Medicina (Kaunas, Lithuania) 60(9), pp.1412. doi: 10.3390/medicina60091412

Abstract: Background and Subject: Hyponatraemia is a common electrolyte disorder. For patients with severe hyponatraemia, intensive care unit (ICU) admission may be required. This will enable close monitoring and allow safe management of sodium levels effectively. While severe hyponatraemia may be associated with significant symptoms, rapid overcorrection of hyponatraemia can lead to complications. We aimed to describe the management and outcomes of severe hyponatraemia in our ICU and identify risk factors for overcorrection. Materials and Methods: This was a retrospective single-centre cohort that included consecutive adults admitted to the ICU with serum sodium < 120 mmol/L between 1 January 2017 and 8 March 2023. Anonymised data were collected from electronic records. We included 181 patients (median age 67 years, 51% male). Results: Median admission serum sodium was 113 mmol/L (IQR: 108-117), with an average rate of improvement over the first 48 h of 10 mmol/L/day (IQR: 5-15 mmol/L). A total of 62 patients (34%) met the criteria for overcorrection at 48 h, and they were younger, presented with severe symptoms (seizures/arrythmias), and had lower admission sodium concentration. They were more likely to be treated with hypertonic saline infusions. Lower admission sodium was an independent risk factor for overcorrection within 48 h, whereas the presence of liver cirrhosis and fluid restriction was associated with normal correction. No difference was identified between the normal and overcorrected cohorts for ICU/hospital length of stay or mortality. Conclusions: In some patients with severe hyponatraemia, overcorrection is inevitable to avoid symptoms such as seizures and arrhythmias, and consequently, we highlight the key factors associated with overcorrection. Overall, we identified that overcorrection was common and concordant with the current literature.

Access full text https://libkey.io/10.3390/medicina60091412

10. Hyponatraemia-treatment standard 2024

Authors: Spasovski, Goce
Publication Date: 2024
Journal: Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association – European Renal Association 39(10), pp.1583–1592

Abstract: Hyponatraemia is the most common electrolyte disorder in hospital patients associated with increased morbidity, mortality, hospital stay and financial burden. The speed of a correction with 3% sodium chloride as a 100- to 150-ml intravenous bolus or continuous infusion depends on the severity and persistence of the symptoms and needs frequent biochemical monitoring. The rapid intermittent administration of hypertonic saline is preferred for treatment of symptomatic hyponatraemia. In asymptomatic mild hyponatraemia, an adequate solute intake with an initial fluid restriction (FR) of 500 ml/day adjusted according to the serum sodium (sNa) levels is preferred. Almost half of the syndrome of inappropriate antidiuretic hormone (SIADH) patients do not respond to FR as first-line therapy. At present, urea and tolvaptan are considered the most effective second-line therapies in SIADH. However, the evidence for guidance on the choice of second-line therapy of hypotonic hyponatraemia is lacking. Oral urea is considered to be a very effective and safe treatment. Mild and asymptomatic hyponatraemia is treated with adequate solute intake (salt and protein) and initial FR with adjustments based on sNa levels. Specific treatment with vaptans may be considered in either euvolaemic or hypervolaemic patients with high ADH activity. In order to ensure optimal patient outcome, close monitoring and readiness for administration of either hypotonic fluids or desmopressin may be crucial in the decision-making process for specific treatment and eventual overcorrection consequences. According to the guidelines, gradual correction and clinical evaluation is preferable over rapid normalization of sNa towards the laboratory reference ranges.

Access full text https://libkey.io/10.1093/ndt/gfae162

11. Glucocorticoids and Water Balance: Implications for Hyponatremia Management and Pituitary Surgery

Authors: Castle-Kirszbaum, Mendel; Goldschlager, Tony; Shi, Margaret D. Y., et al
Publication Date: 2023
Journal: Neuroendocrinology 113(8), pp.785–794

Abstract: Water balance is fundamental to all homeostasis. The hypothalamic-pituitary-adrenal axis influences water balance through the effects of corticotropin-releasing hormone and cortisol on arginine vasopressin secretion and the peripheral effects of cortisol on hemodynamics and renal water handling. In this review, we explored the complex interplay of glucocorticoids with water balance, with particular attention to hyponatremia and pituitary surgery.

Access full text https://libkey.io/10.1159/000530701

12. Evaluation of Desmopressin in Critically Ill Patients with Hyponatremia Requiring 3% Hypertonic Saline

Authors: Tran, Lena K.; Marino, Kaylee K.; DeGrado, Jeremy R., et al
Publication Date: 2021
Journal: The American Journal of the Medical Sciences 361(6), pp.711–717

Abstract: BACKGROUND: Desmopressin (DDAVP) is often used for hyponatremia management but has been associated with increases in hospital length of stay and duration of hypertonic saline use. The purpose of this study was to evaluate hyponatremia management strategies and their effect on sodium correction in critically ill patients requiring 3% hypertonic saline (3HS). METHODS: This retrospective, single-center study included critically ill patients with hyponatremia (serum sodium ≤ 125 mEq/L) receiving 3HS from May 31 2015, to May 31 2019. Patients were divided into those who received 3HS for hyponatremia management (HTS) and those who received proactive or reactive DDAVP in addition to 3HS (D-HTS). Patients in either group could receive rescue DDAVP. The primary outcome was the percentage of patients achieving goal sodium correction of 5-10 mEq/L 24 h after 3HS initiation. RESULTS: Goal sodium correction was achieved in 52.5% of patients in HTS compared to 65.6% of patients in D-HTS (p = 0.21). Patients in HTS had a shorter duration of 3HS infusion (p = 0.0022) with no difference in ICU length of stay, free water intake, urine output, or serum sodium increases 12 and 24 h after receiving 3HS. Overcorrection during any 24- or 48 h period was not statistically different between groups. CONCLUSION: Patients in HTS and D-HTS had similar rates of achieving goal sodium correction at 24 h. A proactive or reactive DDAVP strategy led to an increase in 3HS duration and total amount with no significant difference in rates of overcorrection. Prospective, randomized studies assessing standardized strategies for hyponatremia management and DDAVP administration are warranted.

Request full text https://libkey.io/10.1016/j.amjms.2021.03.012

Posted in Ward Round Update | Leave a comment

Hypokalaemia

Following ward round on 6 October, please find below some reading on renal causes of hypokalaemia.

Please note that inclusion in this blog is not an endorsement of quality.

Please follow local protocols for drug doses.

To access full text you will need an NHS OpenAthens account. Please sign up here if you haven’t already got one.

KnowledgeShare is a current awareness tool which helps you deal with information overload, while ensuring that you receive high quality information on topics that are important to you. Take five minutes to fill in this form and we will send you regular updates on your chosen topic.

DynaMed

DynaMed (2026) Hypokalemia in Adults – Approach to the Patient See also Fanconi Syndrome and Renal Tubular Acidosis (RTA) in Adults

BMJ Best Practice

BMJ Best Practice (2026) Assessment of hypokalaemia

Articles

1. Disorders of Potassium

Authors: Piner, Andrew and Spangler, Ryan
Publication Date: 2026
Journal: Endocrinology and Metabolism Clinics of North America 55(1), pp.35–52

Abstract: Abnormalities in serum potassium are commonly encountered in patients presenting to the emergency department. A variety of acute and chronic causes can lead to life-threatening illness in both hyperkalemia and hypokalemia. Here we summarize the relevant causes, risks, and treatment options for these frequently encountered disorders.

Request full text

2. Hypokalemia

Authors: Castro, Danny and Sharma, Sandeep
Publication Date: 2025
Journal: StatPearls

Abstract: Hypokalemia Overview Hypokalemia is one of the most common electrolyte disturbances seen in clinical practice. The condition is more prevalent than hyperkalemia, though most hypokalemia cases are mild. Although variation exists, an acceptable lower limit for normal serum potassium is 3.5 mmol/L. Hypokalemia is classified according to severity. A serum potassium level of 3 to 3.4 mmol/L is classified as mild. A serum potassium level of 2.5 to 3 mmol/L is classified as moderate. Serum potassium levels less than 2.5 mmol/L are classified as severe. Symptoms of hypokalemia vary depending on the severity and underlying cause but may include muscle weakness, fatigue, cramping, palpitations, and constipation. Severe hypokalemia can lead to life-threatening complications, such as fatal arrhythmias or respiratory muscle paralysis. Hypokalemia must be addressed promptly to prevent complications. Long-term management may involve monitoring potassium levels, adjusting medications, and addressing any underlying medical conditions contributing to hypokalemia. Summary of Potassium Regulation Potassium is a predominantly intracellular electrolyte, the most abundant cation in cell regulation and cellular processes. The fraction of potassium in the extracellular fluid is small. Thus, plasma or serum levels are unreliable indicators of total body potassium stores. The body’s potassium level is tightly regulated by the kidneys, digestive tract, endocrine system, and cells actively participating in transcellular shifts, such as the skeletal muscles. Cellular potassium uptake is promoted by alkalemia, insulin, β-adrenergic stimulation, aldosterone, and xanthines, such as caffeine. Potassium deficiency may arise from various causes, such as poor nutrition, endocrine disorders, diarrhea, medication intake, and prior surgeries. Hypokalemia may thus be a manifestation of a more serious disorder.

Access full text

3. Finding the cause of severe hypokalemia: A 4-step approach

Authors: Leiva-Murillo, Enmanuel A.; Bechtold-Javier, Erwin; Candela-Parrilla, Pol, et al
Publication Date: 2025
Journal: Cleveland Clinic Journal of Medicine 92(12), pp.748–756

Abstract: not available

Access full text

4. Correction of Electrolyte Abnormalities in Critically Ill Patients

Authors: Bulloch, Marilyn N.; Maria Cardinale-King; Cogle, Sarah, et al
Publication Date: 2024
Journal: Intensive Care Research 4(1), pp.19–37

Abstract: Abstract Introduction The majority of patients in the intensive care unit (ICU) are at risk for at least one electrolyte abnormality and critically ill patients are the most vulnerable population to the effects of suboptimal electrolyte levels. These patients have unique characteristics impacting implications of the electrolyte disturbances and management. Areas Covered In the ICU, magnesium, potassium, calcium, phosphorous, and sodium are the most commonly encountered electrolytes that can be abnormal in the critically ill. Critical illness both is affected by and affects disturbances of these electrolytes which can result in more severe illness, longer duration of mechanical ventilation, increased dialysis support, longer length of stay, and increased mortality. Often, patients have multiple imbalances that require correction. Removal or mitigation of the cause should be undertaken whenever possible and should be concurrent with any therapeutic management used to correct the electrolyte imbalance. Selection of medication to correct electrolyte imbalances should be undertaken according to available evidence and drug-specific characteristics that impact medication delivery in the critically ill. Electrolyte disturbances, measurements, and corrections are ubiquitous in the ICU. Published literature on the management of electrolytes in the critically ill is limited. Management should consider factors unique to the critically ill when selecting optimal treatment approach and it is essential to individualize treatment to a patient’s unique needs and adapt management to the patient’s chancing clinical situation.

Access full text

5. Renal Hypokalemia: An Endocrine Perspective

Authors: Culver, Silas A.; Suleman, Nawar; Kavuru, Varun, et al
Publication Date: 2024
Journal: The Journal of Clinical Endocrinology and Metabolism 109(7), pp.1694–1706

Abstract: The majority of disorders that cause renal potassium wasting present with abnormalities in adrenal hormone secretion. While these findings frequently lead patients to seek endocrine evaluation, clinicians often struggle to accurately diagnose these conditions, delaying treatment and adversely impacting patient care. At the same time, growing insight into the genetic and molecular basis of these disorders continues to improve their diagnosis and management. In this review, we outline a practical integrated approach to the evaluation of renal hypokalemia syndromes that are seen in endocrine practice while highlighting recent advances in understanding of the genetics and pathophysiology behind them.

Access full text

6. Optimising patient care: comprehensive evaluation of inpatient hypokalaemia

Authors: Muthaluraj, Gokul Prasanna; Sathyanarayanan, Abinivesh; Larsen, Niels, et al
Publication Date: 2024
Journal: British Journal of Hospital Medicine (London, England : 2005) 85(8), pp.1–7

Abstract: Hypokalaemia is a common electrolyte disorder affecting hospitalised patients. It is associated with adverse outcomes including increased mortality. Inpatients with hypokalaemia need a different approach to workup and management as the aetiologies and progression of the hypokalaemia are distinct to outpatients. Potassium homeostasis is predominantly maintained by renal potassium handling. The clinical manifestations of hypokalaemia depend on the severity of hypokalaemia, however, most of the findings are non-specific. The approach to management is guided by the severity of the hypokalaemia and the underlying aetiology. Oral potassium replacement can be used in many cases of mild hypokalaemia. Intravenous replacement of potassium is necessary for many inpatients. Close monitoring is essential to ensure adequacy and to prevent adverse outcomes. An interdisciplinary approach with critical care input is needed in severe cases, and in patients where routine intravenous replacement may not be feasible (e.g., patients with heart failure). In addition to replacement, the cornerstone of management is a comprehensive review of the patient to identify the underlying cause of the hypokalaemia and the factors sustaining it. In patients in whom the cause is not apparent, or the potassium does not improve as anticipated, a referral to nephrology or endocrinology should be considered. This paper reviews the assessment of hypokalaemia in a hospital setting. It is aimed at early career doctors on the wards to help carry out a thorough evaluation. It also provides a useful framework for management.

Access full text

7. Understanding renal tubular acidosis

Authors: Wang, Samuel Sherng Young; Tang, Haoming; Ho, Wen Qi Jane, et al
Publication Date: 2024
Journal: British Journal of Hospital Medicine (London, England : 2005) 85(10), pp.1–12

Abstract: Renal tubular acidosis is a group of disorders characterised by metabolic acidosis, hyperchloraemia, normal anion gap, and potassium imbalance. Genetic mutations, drugs or acquired disorders disrupt the function of various transport proteins and enzymes in the renal tubules, causing diminished bicarbonate reabsorption or inability to excrete hydrogen ions, leading to proximal (type 2) and distal (type 1) renal tubular acidosis, respectively. These conditions are typically associated with hypokalaemia, which, if severe, can cause muscle paralysis and dangerous cardiac arrhythmias. A rare mixed variant (type 3), including features of both type 1 and type 2 renal tubular acidosis, has also been described. On the other hand, aldosterone deficiency or resistance leads to the hyperkalaemic form of renal tubular acidosis (type 4). If untreated, renal tubular acidosis can lead to long-term severe complications such as growth retardation, osteoporosis, rickets, osteomalacia, and renal calculi. Moreover, renal tubular acidosis might be the initial presentation of a more severe underlying pathology, such as autoimmune disease or plasma cell dyscrasias. A better understanding of the condition can help physicians diagnose and treat it early and prevent adverse outcomes.

Access full text

Posted in Ward Round Update | Leave a comment

Patients with substance use disorders

Please find below some reading on the critical care management of patients with a history of recreational substance use or substance use disorders.

Please note that inclusion in this blog is not an endorsement of quality.

Please follow local protocols for drug doses.

To access full text you will need an NHS OpenAthens account. Please sign up here if you haven’t already got one.

KnowledgeShare is a current awareness tool which helps you deal with information overload, while ensuring that you receive high quality information on topics that are important to you. Take five minutes to fill in this form and we will send you regular updates on your chosen topic.

Guidance

Faculty of Pain Medicine RCoA Opioids aware see especially the sections on Patients with substance misuse and Substance misuse: acute pain management

Articles

1. Association Between Prior Substance Use and Sedation and Analgesia Requirements Among Mechanically Ventilated Adults With Critical Illness

Authors: Feeney, Megan E. and Bosch, Nicholas A.
Publication Date: 2026
Journal: The Annals of Pharmacotherapy 60(8), pp.754–763

Abstract: BACKGROUND: Patients with substance use disorders (SUD) are at an increased risk of admission to intensive care units (ICUs) and the relationship between SUD and commonly used sedative and analgesic medications remains understudied. OBJECTIVE: The objective of this study was to describe associations between substance use disorder (SUD) and medication dose requirements in patients with critical illness requiring invasive mechanical ventilation (IMV). METHODS: This was a single center, retrospective study of adult patients admitted to an ICU between January 1, 2017, to October 31, 2022 who were initiated on IMV within 48 hours. The primary outcome was median total daily dose of each sedative and analgesic medication received, grouped as follows: parenteral opioids, benzodiazepines, propofol, and dexmedetomidine. Multivariable median regression was used to determine associations between SUD and median daily dose after adjustment for demographic and clinical covariables. RESULTS: Of 1290 included patients, 358 (27.8%) had a documented SUD present on admission. In unadjusted analyses, patients with SUD received higher median daily doses of parenteral opioids (197.5 MME [IQR 61.9-344.3] vs 162.2 MME [IQR 60.3-324.6]) and propofol (26 640 µg/kg [IQR 11 659-43 518] vs 23 248 µg/kg [IQR 10 510-38 870). No differences in median daily dose were noted for parenteral benzodiazepines or dexmedetomidine. In adjusted analyses, associations between SUD and median daily dose of parenteral opioids (β, 18.1 MME; 95% CI, -13.6 to 49.4) or propofol (β, 1699.9 µg/kg; 95% CI, -2477.1 to 5882.8) were no longer present. CONCLUSION AND RELEVANCE: Results of unadjusted analyses aligned with prior studies reporting increased dose requirements of sedation and analgesia in patients with SUD; however, associations were diminished after adjustment for clinical and demographic covariables. Our results suggest the presence of SUD alone may not necessitate empirically higher medication doses in patients with SUD receiving IMV during critical illness.

Request full text

2. Management of the Critically Ill Patient with Opioid Use Disorder

Authors: Imperato, Nicholas S. and Spadaro, Anthony
Publication Date: 2026
Journal: Emergency Medicine Clinics of North America 44(4), pp.775–788

Abstract: The management of critically ill patients with opioid use disorder presents a unique challenge, as overdose, withdrawal, or concomitant intoxication, due to an unregulated drug supply, leads to physiologic changes that potentially impact standard treatment. This review article outlines an emergency medicine-focused approach for early recognition and stabilization of opioid overdose or withdrawal. Topics include naloxone, use of medications for opioid use disorder, recognition of concurrent intoxication, treatment of α2-agonist withdrawal, multimodal analgesia, and sedation for opioid-tolerant patients. The acute management of opioid use disorder is an opportunity to prevent withdrawal-related decompensation, improve comfort, and support ongoing engagement in treatment.

Request full text

3. Comprehensive toxicology testing and clinical outcomes of ED patients with unregulated drug poisoning

Authors: Martens, Anastasia; Li, Elva; Georgi, Katerina, et al
Publication Date: 2026
Journal: Cjem

Abstract: OBJECTIVES: Unregulated drugs place a significant burden on individuals and the healthcare system, yet relatively little is known about the mix of substances implicated in the current polydrug crisis and their clinical effects. The current study aims to describe the toxicology and clinical outcomes of unregulated drug poisoning. METHODS: We conducted a cross-sectional study at a tertiary hospital in Vancouver, British Columbia. Eligible patients were those presenting to the emergency department (ED) with suspected unregulated drug overdose and residual blood samples available for analysis. Chart review was performed to extract relevant clinical data, and liquid chromatography-tandem quadruple mass spectrometry was applied to blood samples to detect a broad panel of substances beyond routine ED toxicology screens. RESULTS: From 148 eligible patients, we randomly selected 69 for toxicology testing (mean age 43 years; 74% male). Amphetamines (94%), fentanyl or analogues (67%), and unregulated benzodiazepines (64%) were most prevalent. Polysubstance exposure was nearly universal, with 91% positive for three or more drug classes, 83% for four or more, and nearly half (49%) for six or more concurrently. Clinical interventions were frequent, with naloxone administered to 59% of patients, 25% requiring-assisted ventilation (including two who required intubation). Twenty-eight percent of patients were admitted to hospital, with 4% admitted to intensive care. Complications included loss of consciousness (55%), hypoxia (22%), seizures (9%), severe agitation (6%) and rhabdomyolysis (3%). CONCLUSION: Unregulated drug poisoning in Vancouver, British Columbia was characterized by polysubstance exposure and frequent complications. Detailed toxicological analysis revealed high rates of unregulated benzodiazepines and stimulant co-detection with opioids, underscoring risks beyond opioid toxicity alone. Clinicians should be aware that unregulated drug poisoning involves multiple substances and may therefore have atypical presentations and/or incomplete response to standard therapy.

Request full text

4. Substance-Use Disorders in Critically Ill Patients: A Narrative Review

Authors: Piland, Rebecca; Jenkins, Russell Jack; Darwish, Dana, et al
Publication Date: 2025
Journal: Anesthesia and Analgesia 140(3), pp.604–615

Abstract: Substance-use disorders (SUDs) represent a major public health concern. The increased prevalence of SUDs within the general population has led to more patients with SUD being admitted to intensive care units (ICUs) for an SUD-related condition or with SUD as a relevant comorbidity. Multiprofessional providers of critical care should be familiar with these disorders and their impact on critical illness. Management of critically ill patients with SUDs is complicated by both acute exposures leading to intoxication, the associated withdrawal syndrome(s), and the physiologic changes associated with chronic use that can cause, predispose patients to, and worsen the severity of other medical conditions. This article reviews the epidemiology of substance use in critically ill patients, discusses the identification and treatment of common intoxication and withdrawal syndromes, and provides evidence-based recommendations for the management of patients exposed to chronic use.

Access full text

5. Evaluation of pre-hospital cannabis exposure and hospital opioid utilization in a trauma population: A retrospective cohort

Authors: Chang, Alexander J.; Mallat, Ali F.; Edwards, Marc J., et al
Publication Date: 2024
Journal: Injury 55(5), pp.111305

Abstract: PURPOSE: Cannabis utilization has increased over time for recreational and medical purposes due to its legalization or decriminalization. The effects of cannabis use on opioid utilization are not well understood. The primary objective was to evaluate the total opioid utilization, measured in morphine milligram equivalents (MME), in hospitalized trauma patients that tested positive for tetrahydrocannabinol (THC) on a urine drug screen (UDS). METHODS: This was a retrospective, cohort study in a level 1 trauma center between 10/17/17 and 12/31/19. Adult trauma patients (aged 15 years and older) who had a UDS completed within 48 h of hospital arrival were eligible for inclusion. Patients were excluded for a hospitalization >14 days, death within 24 h, severe alcohol withdrawal, prescribed cannabinoids, high daily opioid use prior-to-arrival, or transitioned to hospice or palliative care. Group assignments were determined based on the presence or absence of THC on the UDS. RESULTS: The analysis included 750 patients with 160 (21 %) THC positive patients. The population were primarily male (64.6 %), median age of 56 years [IQR 35-72], with blunt (93 %) injuries from motor vehicle crash or falls (79 %). The THC group was more likely to have other substances present, including amphetamines, benzodiazepines, opiates, and cocaine. The THC group had a higher median injury severity score (10 [IQR 5-17] vs. 9 [5-14], p = 0.0056), and maximum abbreviated injury score (3 [IQR 2-3] vs. 2 [IQR 2-3], p = 0.0009). The THC group had a total higher median opioid utilization during the hospitalization (155 [IQR 68-367] vs. 62 [IQR 13-175] MME; p < 0.0001), which included higher opioid use in the emergency department, floor, and intensive care unit. There were no significant differences in secondary outcomes except the THC group was more likely to receive an opioid prescription at discharge and more likely to require mechanical ventilation. Based on multivariable regression analyses, other variables were associated with increased opioid utilization. CONCLUSION: Pre-existing THC exposure may be associated with an increased hospital opioid utilization in a trauma population. However, other variables may also play a role in opioid utilization.

Request full text

6. Risk Factors for Increased Opioid Use During Postoperative Intensive Care

Authors: Guichard, Lauriane; Engoren, Milo C.; Li, Yi-Ju, et al
Publication Date: 2024
Journal: Critical Care Explorations 6(11), pp.e1172

Abstract: IMPORTANCE: In the ICU, opioids treat pain and improve ventilator tolerance as part of an analgosedation approach. Identifying predictors of opioid consumption during the ICU course might highlight actionable items to reduce opioid consumption. OBJECTIVES: To identify risk factors for opioid use during a postoperative ICU course. DESIGN, SETTING, AND PARTICIPANTS: Patients enrolled in the Michigan Genomics Initiative single-center prospective observational cohort study completed baseline preoperative sociodemographic and mental/physical health questionnaires and provided blood samples for genetic analysis. Included patients were 18 years old and older, admitted to ICU postoperatively, and received opioids postoperatively. MAIN OUTCOMES AND MEASURES: The primary outcome was ICU mean daily oral morphine equivalent (OME) use. The association between OME and phenotypic risk factors and genetic variants previously associated with pain were analyzed through univariable and multivariable linear regression models. RESULTS: The cohort consisted of 1865 mixed-surgical patients with mean age of 56 years (sd, 15 yr). Preoperative opioid users were more likely to continue to receive opioids throughout their ICU stay than opioid-naive patients. OME (log10 scale) was most strongly associated with ICU mechanical ventilation (β = 0.27; 95% CI, 0.15-0.38; p 24 hours of mechanical ventilation), preoperative opioid use (β = 0.22; 95% CI, 0.16-0.29; p < 0.0001; effect size 1.67 for receiving preoperative opioids), major surgery (β = 0.21; 95% CI, 0.12-0.30; p < 0.0001; effect size 1.62 compared with minor surgery), and current/former illicit drug use (β = 0.12; 95% CI, 0.01-0.23; p = 0.04; effect size 1.30 for drug use). Younger age, centralized pain, and longer anesthetic duration were also significantly associated with OME but with smaller effect sizes. Selected genetic variants (FKBP5, COMT, and OPRM1) were not associated with OME use. CONCLUSIONS AND RELEVANCE: Mechanical ventilation and preoperative opioids were the strongest risk factors for postoperative ICU opioid consumption, whereas psychologic factors and genetic variants were not associated.

Access full text

7. Determinants of Admission to Critical Care Following Acute Recreational Drug Toxicity: A Euro-DEN Plus Study

Authors: Noseda, Roberta; Franchi, Matteo; Pagnamenta, Alberto, et al
Publication Date: 2023
Journal: Journal of Clinical Medicine 12(18), pp.5970. doi: 10.3390/jcm12185970

Abstract: This study aimed to characterize patients admitted to critical care following Emergency Department (ED) presentation with acute recreational drug toxicity and to identify determinants of admission to critical care. A retrospective multicenter matched case-control study was conducted by the European Drug Emergency Network Plus (Euro-DEN Plus) over the period 2014-2021. The cases were ED presentations with acute recreational drug toxicity admitted to critical care, the controls consisted of ED presentations with acute recreational drug toxicity medically discharged directly from the ED. The potential determinants of admission to critical care were assessed through multivariable conditional stepwise logistic regression analysis and multiple imputation was used to account for the missing data. From 2014 to 2021, 3448 Euro-DEN Plus presentations involved patients admitted to critical care (76.9% males; mean age 33.2 years; SD 10.9 years). Patient age ≥35 years (as compared to ≤18 years) was a determinant of admission to critical care following acute recreational drug toxicity (adjusted odds ratio, aOR, 1.51, 95% confidence interval, CI, 1.15-1.99), along with polydrug use (aOR 1.39, 95% CI 1.22-1.59), ethanol co-ingestion (aOR 1.44, 95% CI 1.26-1.64), and the use of gamma-hydroxybutyrate/gamma-butyrolactone (GHB/GBL, aOR 3.08, 95% CI 2.66-3.57). Conversely, lower odds of admission to critical care were associated with the use of cocaine (aOR 0.85, 95% CI 0.74-0.99), cannabis (aOR 0.44, 95% CI 0.37-0.52), heroin (aOR 0.80, 95% CI 0.69-0.93), and amphetamine (aOR 0.65, 95% CI 0.54-0.78), as was the arrival to the ED during the night (8 p.m.-8 a.m., aOR 0.88, 95% CI 0.79-0.98). These findings, which deserve confirmation and further investigation, could contribute to a more complete understanding of the decision-making process underlying the admission to critical care of patients with acute recreational drug toxicity.

Access full text

8. Cannabis use in the intensive care setting: A scoping review

Authors: Renger, Laura; Pathmanathan, Kevin; Glynn, Rosie, et al
Publication Date: 2023
Journal: Journal of Critical Care 78, pp.154397

Abstract: PURPOSE: Cannabis is the most used recreational drug worldwide, and is increasingly used for medicinal purposes, however little is known about its impact on patients in intensive care units (ICU). Our objective was to identify key themes in the literature surrounding cannabis in the ICU and identify future research priorities. METHODS: Four databases were systematically searched for literature investigating the impact of cannabis, and evidence for its therapeutic use, in adult ICU patients. RESULTS: Of 2589 articles screened, 22 articles were included for analysis. Cannabis-associated admissions were primarily related to an outbreak of vaping associated lung injury, and synthetic cannabinoid toxicity. Studies on the impact of cannabis use on outcomes were mostly limited to trauma and burns populations, with an inconsistent mortality benefit, and a trend towards increased pain scores and analgesic requirements found. There is minimal research on its therapeutic uses in ICU, with two trials investigating the use of a synthetic cannabinoid in patients with severe traumatic brain injury, with ultimately no significant effect on intracranial pressure found. CONCLUSIONS: There is a paucity of studies investigating the impact of cannabinoids or their therapeutic uses in critically ill patients, with further research in this area needed.

Request full text

9. Critical care for patients with substance use disorders

Authors: Steel, Tessa L.; Bhatraju, Elenore P. and Hills-Dunlap, Kelsey
Publication Date: 2023
Journal: Current Opinion in Critical Care 29(5), pp.484–492

Abstract: PURPOSE OF REVIEW: To examine the impact of substance use disorders (SUDs) on critical illness and the role of critical care providers in treating SUDs. We discuss emerging evidence supporting hospital-based addiction treatment and highlight the clinical and research innovations needed to elevate the standards of care for patients with SUDs in the intensive care unit (ICU) amidst staggering individual and public health consequences. RECENT FINDINGS: Despite the rapid increase of SUDs in recent years, with growing implications for critical care, dedicated studies focused on ICU patients with SUDs remain scant. Available data demonstrate SUDs are major risk factors for the development and severity of critical illness and are associated with poor outcomes. ICU patients with SUDs experience mutually reinforcing effects of substance withdrawal and pain, which amplify risks and consequences of delirium, and complicate management of comorbid conditions. Hospital-based addiction treatment can dramatically improve the health outcomes of hospitalized patients with SUDs and should begin in the ICU. SUMMARY: SUDs have a significant impact on critical illness and post-ICU outcomes. High-quality cohort and treatment studies designed specifically for ICU patients with SUDs are needed to define best practices and improve health outcomes in this vulnerable population.

Request full text

10. Substance Use, Intoxication, and Withdrawal in the Critical Care Setting

Authors: Donroe, Joseph H. and Tetrault, Jeanette M.
Publication Date: 2017
Journal: Critical Care Clinics 33(3), pp.543–558

Abstract: Substance use is common among individuals admitted to the critical care setting and may complicate treatment of underlying disorders. Management issues include the effects of intoxication as well as the risk posed by substance-withdrawal syndromes in patients being treated for critical illness. This article reviews the epidemiology of substance use in this population and the identification and treatment of common intoxication and withdrawal syndromes. The authors stress the importance of long-term planning as part of the overall treatment protocol beyond the acute presentation.

Request full text

Posted in Ward Round Update | Leave a comment

Guillain-Barre syndrome: long term outcomes in older patients

Please find below some reading on long term outcomes and incidence of autonomic disturbances in Guillain-Barre syndrome patients aged 60+ years.

Please note that inclusion in this blog is not an endorsement of quality.

Please follow local protocols for drug doses.

To access full text you will need an NHS OpenAthens account. Please sign up here if you haven’t already got one.

KnowledgeShare is a current awareness tool which helps you deal with information overload, while ensuring that you receive high quality information on topics that are important to you. Take five minutes to fill in this form and we will send you regular updates on your chosen topic.

DynaMed and BMJ Best Practice

DynaMed (2025) Guillain-Barre Syndrome – prognosis

BMJ Best Practice (2026) Guillain-Barre syndrome – prognosis

Guidelines

European Academy of Neurology/Peripheral Nerve Society (2023) Guideline on diagnosis and treatment of Guillain-Barré syndrome See the section on prognosis towards the end of the guideline.

Neurocritical Care Society (2023) Guidelines for neuroprognostication in adults with Guillain–Barré syndrome

Articles

1. Autonomic Dysfunction After Guillain-Barré Syndrome: Evidence from Comprehensive Autonomic Testing

Authors: Theologou, Rafaella; Barkoula, Theodora; Ioannou, Christiana, et al
Publication Date: 2026
Journal: Journal of Clinical Medicine 15(15), pp.5963. doi: 10.3390/jcm15155963

Abstract: Background/Objectives: Guillain-Barré syndrome (GBS) is an acute immune-mediated disorder of the peripheral nervous system. Autonomic involvement in GBS occurs during the acute phase and may persist into the recovery phase. This study aimed to investigate the autonomic nervous system’s function in GBS sufferers. Methods: A cross-sectional exploratory study was conducted at the Clinical Neurophysiology Laboratory, Medical School, University of Cyprus. Eligible patients were previously hospitalized with GBS. Autonomic nervous system assessment included the Ewing battery using the Finapres Nova system as well as sudomotor assessment. Results: Seventeen patients were recruited (53% female; mean age 58.7 ± 14.1 years). The mean follow-up time since diagnosis was 15.5 ± 13.2 months (range 1-45 months). At follow-up, 4/17 patients (24%) demonstrated an abnormal heart rate (HR) response to standing, 3/17 patients (18%) exhibited an abnormal systolic blood pressure (BP) response to standing, and 4/17 patients (24%) exhibited an abnormal diastolic BP response to standing. One patient (6%) demonstrated an abnormal HR response during deep breathing, while another showed an abnormal diastolic BP response during the handgrip test. Overall, 6/17 patients (35%) showed abnormal findings in at least one component of the Ewing battery, and 3/17 (18%) fulfilled the criteria for definite generalised dysautonomia. Two patients (12%) demonstrated abnormal sympathetic skin response (SSR) results; both fulfilling the criteria for dysautonomia based on the Ewing battery. Conclusions: Autonomic dysfunction may be present in GBS patients beyond the acute phase, even in the absence of overt autonomic symptoms. Larger prospective studies with serial autonomic assessments are required to better characterise the long-term course and clinical significance of dysautonomia in GBS.

Access full text

2. Long-Term Outcomes After Guillain-Barré Syndrome: A Systematic Review of Functional Recovery, Residual Symptoms, and Quality of Life

Authors: Zahir Hussain, Sharafath Hussain and Moe, Zaw
Publication Date: 2026
Journal: Cureus 18(4), pp.e106509

Abstract: Guillain-Barré syndrome (GBS) is an acute immune-mediated polyradiculoneuropathy characterized by rapidly progressive weakness and variable recovery trajectories. Although many patients regain functional independence after the acute phase, increasing evidence suggests that long-term sequelae such as fatigue, pain, residual disability, and reduced health-related quality of life are common and frequently under-recognized. However, contemporary evidence on long-term outcomes after GBS remains dispersed across multiple study designs and populations, making an updated synthesis clinically relevant. This systematic review aimed to evaluate long-term outcomes reported at or beyond six months after GBS onset, focusing on functional recovery, persistent symptoms, and patient-reported quality of life. A systematic search of PubMed was conducted for studies published between January 2014 and November 2025 using predefined search terms related to GBS and long-term outcomes. Studies reporting outcomes beyond six months after disease onset were included, encompassing cohort studies, clinical trials with follow-up, qualitative studies, and systematic reviews. Due to heterogeneity in study design, outcome measures, and follow-up duration, findings were synthesized narratively. Across the included literature, most patients demonstrated substantial neurological recovery within the first year; however, a clinically meaningful proportion continued to experience persistent symptoms beyond one to three years. Fatigue and neuropathic pain were among the most frequently reported long-term sequelae and were major contributors to impaired quality of life despite apparent motor recovery. Residual functional limitations, participation restrictions, and psychosocial impacts were also commonly reported. Factors associated with poorer long-term outcomes included older age, severe disease at presentation, requirement for mechanical ventilation, autonomic dysfunction, and axonal electrophysiological patterns. These findings highlight that recovery from GBS is often incomplete despite improvement in neurological function. Long-term follow-up incorporating rehabilitation, symptom-directed management, and patient-reported outcome measures may be essential to better address persistent morbidity and optimize quality of life in GBS survivors.

Access full text

3. Predictors of poor prognosis in Guillain-Barre’ syndrome: a study of 22 years from a single Italian Center

Authors: Ariatti, Alessandra; Mazzoli, Marco; Bastia, Elisabetta, et al
Publication Date: 2025
Journal: Journal of the Neurological Sciences 475, pp.123588

Abstract: BACKGROUND: The clinical course and outcome of the Guillain-Barré syndrome (GBS) are diverse and vary among regions, which complicates the management and evaluation of treatment effects in individual patients. OBJECTIVE: To identify predictors of poor prognosis identified by the inability to walk unaided 10 m across an open space (GBS disability score ≥ 3) at 4, 24 and 52 weeks after onset in 230 adults Italian GBS patients, admitted to Neurology Unit, Modena (Italy) during a period of 22 years starting from 2000. METHODS: In this study, 230 patients were collected and analyzed retrospectively. We studied demographic features, clinical presentation, cranial nerve and neck weakness involvement, electrophysiologic phenotype, disease course, associated cardiovascular comorbidities, presence of autonomic dysfunction. The used statistical models were univariable logistic, univariable and multivariable Cox regression analyses. RESULTS: Older age at onset, weakness of neck muscles and involvement of cranial nerves (CNI), low extremity strength at entry, mechanical ventilation (MV) need, autonomic dysfunction, presence of associated cardiovascular disorders, electrophysiological features of axonal damage, treatment related fluctuations (TRF) were predictors of poor outcome in 230 Italian GBS. CONCLUSIONS: We studied in 230 Italian GBS patients over 22 years the role of main clinical and electrophysiological predictors of poor outcome, which included older age at onset, CNI, neck muscle weakness, low MRCss at entry, dysautonomia, TRF, MV need, features of axonal damage on NCS, associated cardiovascular disorders.

Request full text

4. Guillain-Barré Syndrome in Older People-A Case Report and Literature Review

Authors: Chen, Xiaomei; Ko, Win; Waseem, Fiza, et al
Publication Date: 2025
Journal: Diseases (Basel, Switzerland) 13(9), pp.306. doi: 10.3390/diseases13090306

Abstract: Guillain-Barré syndrome (GBS) is the most common acute inflammatory motor polyneuropathy. It affects all age groups, but the incidence increases with increasing age. Before manifesting with neurological symptoms, it is usually preceded by a prodromal phase of infection, most commonly respiratory or gastrointestinal. Pathologically, it is a post-infection immune disorder. The immune response is due to mimicry between the infecting agent and axolemmal surface molecules, which triggers an acute immune injury that leads to blockade of nerve conduction. Age-related decline in immune function plays a role in the increased prevalence and severity of GBS in older people. Typical neurological manifestations are ascending paralysis, areflexia and cranial nerve involvement, but sensory loss is uncommon. In up to 25% of cases, autonomic dysfunction occurs, which includes cardiovascular, sudomotor, gastrointestinal or genitourinary symptoms. The development of autonomic dysfunction in GBS is associated with poor prognosis. We report a case of a 78-year-old man who presented with a predominant autonomic dysfunction that led to a delay in the diagnosis. Because of the multiple morbidities associated with old age, the diagnosis of GBS presentation with autonomic dysfunction, without the typical neurological clinical pattern, may be attributed to the existing comorbidities. Therefore, clinical suspicion and close monitoring with respect to the development of autonomic dysfunction, from the first day of hospital admission, are important. The main diagnostic tests are cerebrospinal fluid analysis looking for protein-cell dissociation and nerve conduction studies to confirm the neuropathy. Treatment involves general supportive care, specific immunological intervention by intravenous immunoglobulins or plasma exchange courses and neurorehabilitation. Severe cases may require intensive care admission and mechanical ventilation. More than 80% of cases will fully recover, but 10% may have residual disability, with mortality estimated at 3-7%. Older age, multiple morbidities, severe weakness, autonomic dysfunction and the need for mechanical ventilation are poor prognostic factors.

Access full text

5. Guillain-Barré syndrome: a comprehensive review

Authors: Bellanti, Roberto and Rinaldi, Simon
Publication Date: 2024
Journal: European Journal of Neurology 31(8), pp.e16365

Abstract: Guillain-Barré syndrome (GBS) is a potentially devastating yet treatable disorder. A classically postinfectious, immune-mediated, monophasic polyradiculoneuropathy, it is the leading global cause of acquired neuromuscular paralysis. In most cases, the immunopathological process driving nerve injury is ill-defined. Diagnosis of GBS relies on clinical features, supported by laboratory findings and electrophysiology. Although previously divided into primary demyelinating or axonal variants, this dichotomy is increasingly challenged, and is not endorsed by the recent European Academy of Neurology (EAN)/Peripheral Nerve Society (PNS) guidelines. Intravenous immunoglobulin and plasma exchange remain the primary modalities of treatment, regardless of the electrophysiological subtype. Most patients recover, but approximately one-third require mechanical ventilation, and 5% die. Disease activity and treatment response are currently monitored through interval neurological examination and outcome measures, and the potential role of fluid biomarkers is under ongoing scrutiny. Novel potential therapies for GBS are being explored but none have yet modified clinical practice. This review provides a comprehensive update on the pathological and clinical aspects of GBS for clinicians and scientists.

Access full text

6. Prognostic Factors in Elderly Patients With Guillain-Barré Syndrome: Does Age Matter?

Authors: Briseño-Godínez, Maria Eugenia; Arauz, Antonio; López-Hernández, Juan Carlos, et al
Publication Date: 2021
Journal: The Neurohospitalist 11(4), pp.303–309

Abstract: INTRODUCTION: Twenty to 40% of Guillain Barré syndrome (GBS) patients will not be able to walk independently despite effective treatment. Older patients carry additional risks for worse outcomes. METHODS: A single center, ambispective cohort study was performed. Only subjects ≥18 years with a 3-month follow-up were included. Elderly patients were considered as a whole if ≥ 60 years. Demographics, CSF and nerve conduction studies were compared. A binomial logistic regression and Kaplan-Meier analyses were carried out to estimate good prognosis (Hugues ≤2) at 3-month follow-up. RESULTS: From 130 patients recruited, 27.6% were elderly adults. They had a more severe disease, higher mEGOS and more cranial nerve involvement. Age ≥70 years, invasive mechanical ventilation and axonal subtype, portrayed an unfavorable 3-month outcome. Further analysis demonstrated an earlier recovery in independent walk at 3 months for patients <70 years. CONCLUSIONS: Elderly patients with GBS have a more severe disease at admission and encounter worse prognosis at 3-month follow-up, especially those above 70 years.

Access full text

7. Readmissions After Guillain-Barre Syndrome: Nationally Representative Data

Authors: Roberts, Mallory; Jin, Peter; Shin, Susan, et al
Publication Date: 2021
Journal: Journal of Clinical Neuromuscular Disease 22(4), pp.183–191

Abstract: OBJECTIVES: We aimed to obtain nationally representative data on hospital readmission rates after Guillain-Barre syndrome (GBS). METHODS: International Classification of Disease, Ninth Revision codes from the 2013 National Readmissions Database identified adult GBS admissions, comorbidities, and readmission diagnoses. Logistic regression estimated odds ratios (ORs) for readmission. RESULTS: Of 2109 GBS admissions identified, 20.8% were readmitted within 1 year and 12.2% within 30 days. Age did not predict readmission. Plasmapheresis use showed a nonsignificant trend toward readmission versus intravenous immunoglobulin use [OR 1.43, 95% confidence interval (CI) 1.00-2.051, P = 0.050]. Respiratory failure (OR 1.70, 95% CI 1.23-2.35, P = 0.0014), heart failure (OR 2.14, 95% CI 1.25-3.66, P = 0.0057), and renal failure (OR 2.00, 95% CI 1.20-3.32, P = 0.0078) predicted readmission. Top readmission diagnoses included GBS or chronic inflammatory demyelinating polyneuropathy (42.0%) and sepsis (3.5%). CONCLUSIONS: One-fifth of GBS patients were readmitted within 1 year. Comorbid illnesses and respiratory complications increased a readmission risk but age did not.

Request full text

8. Guillain-Barré syndrome in the elderly

Authors: Peric, Stojan; Berisavac, Ivana; Stojiljkovic Tamas, Olivera, et al
Publication Date: 2016
Journal: Journal of the Peripheral Nervous System : JPNS 21(2), pp.105–110

Abstract: The aim of the study was to analyze specific features of Guillain-Barré syndrome (GBS) in old people. The study included 403 GBS patients (62% young [80 years]). Diagnosis of GBS was made according to the National Institute of Neurological Disorders and Stroke (NINDS criteria). Severe disability (GBS disability score of >3) at nadir was more common in old compared with young patients (p = 0.0001) as was mortality (9% vs. 2%, respectively). Acute motor and sensory axonal neuropathy and hyponatremia were more common in old compared with young patients (12% vs. 6% and 27% vs. 18%, respectively, p = 0.04). A positive history for malignancy was more than three times more common in old than young patients (11% vs. 3%, respectively, p = 0.01). Disability on nadir was similar in young-old and old-old subjects with disability on discharge being more severe in old-old (p = 0.04) suggesting slower recovery in this subgroup. Bulbar symptoms were more common in old-old compared with young-old (50% vs. 19%, respectively, p = 0.01). Comorbidities were present in virtually all old-old patients compared with 66% of young-old patients (p = 0.04). In conclusion, Elderly patients, and especially old-old patients, with GBS have more severe disease with slower recovery than do younger patients.

Access full text

9. Residual disability 10 years after falling ill in Guillain-Barré syndrome: a prospective follow-up study

Authors: Forsberg, Anette; Press, Rayomand and Holmqvist, Lotta Widén
Publication Date: 2012
Journal: Journal of the Neurological Sciences 317(1-2), pp.74–79

Abstract: OBJECTIVE: To describe residual disability 10years after onset of Guillain-Barré syndrome (GBS) and longitudinal changes from 2weeks after onset until 10years afterwards. The Erasmus GBS Outcome score (EGOS) was applied for predicting prognosis at 2 and 10years. METHODS: Twenty-nine patients, mean age at onset 49years, were followed prospectively from 2weeks to 10years after GBS onset. Measures included; GBS disability score, EGOS, Barthel Index, Frenchay Activity Index, Sickness Impact Profile (SIP), Overall Neuropathy Limitations Scale (ONLS), Walk-12, and Fatigue Severity Scale. RESULTS: At 10years, the facial paralysis found in 5 participants at 2years was still present, 11 participants (38%) experienced paresthesia, 6 (21%) had limitations in their arms, and 15 (52%) had limitations in walking. Decreased health-related quality of life on comparison to the general population was seen in the physical dimension of SIP at 10years. The median EGOS at 2weeks was 4.5, which correlated highly only with the Barthel Index at 2years and the ONLS arm scale at 10years. CONCLUSION: The residual disabilities at 1-2years comprised mainly of reduced walking ability, and are still persistent 10years after GBS onset. For some individuals, facial paralysis caused major disability. The EGOS only partly predicted residual disability at 2 and 10years after onset.

Access full text

10. Factors associated with long-term functional outcomes and psychological sequelae in Guillain-Barre syndrome

Authors: Khan, F.; Pallant, J. F.; Ng, L., et al
Publication Date: 2010
Journal: Journal of Neurology 257(12), pp.2024–2031

Abstract: To examine factors impacting long-term health-related outcomes in survivors of Guillain-Barre syndrome (GBS). Seventy-six consecutive patients with definite GBS admitted to the Royal Melbourne Hospital (1996-2009) were reviewed in the neurorehabilitation clinics. They underwent a structured interview designed to assess the impact of GBS on their current activity and restriction in participation using validated questionnaires: Functional Independence Measure (FIM), Perceived Impact of Problem Profile (PIPP) and Depression Anxiety Stress Scale (DASS). Their sociodemographic and disease severity data were obtained from the medical record. The 76 patients [60% male, mean age 56 years, median time since GBS 6 years (range 1-14 years)] showed good functional recovery (median motor FIM score 90). However, 16% reported moderate to extreme impact on their ability to participate in work, family, and social activities; and 22% substantial impact on mood, confidence and ability to live independently. More reported moderate to extreme depression (18%), anxiety (22%) and stress (17%) compared with the normative Australian population (13%). Factors associated with poorer current level of functioning and wellbeing included: females, older patients (57+ years), acute hospital stay (>11 days), those treated in intensive care and those discharged to rehabilitation. No associations were found between the Medical Research Council (MRC) Motor Scale Rating scores at admission, nor time since GBS diagnosis (≤6 vs. >6 years) on outcomes used. CONCLUSION: GBS is complex and requires long-term management of psychological sequelae impacting activity and participation.

Access full text

11. Mechanical ventilation in Guillain-Barré syndrome: does age influence functional outcome?

Authors: Köhrmann, Martin; Huttner, Hagen B.; Nowe, Tim, et al
Publication Date: 2009
Journal: European Neurology 61(6), pp.358–363

Abstract: PURPOSE: To examine the effects of age on differences in the clinical course and functional outcome of mechanically ventilated Guillain-Barré syndrome (GBS) patients. METHODS: 32 consecutive patients with GBS in need of mechanical ventilation were divided into two groups: (1) 15 patients or=65 years. Length of ventilation, therapy, incidence of bulbar involvement, dysautonomia, preceding infections, need for tracheostomy, mortality, and functional outcome at 1-year follow-up using the Hughes outcome scale were analyzed. RESULTS: The groups were comparable regarding treatment, lesion type, incidence of bulbar involvement, dysautonomia, preceding infections and duration of ventilation. The majority of patients (75%) received combination therapy (intravenous immunoglobulin and plasma exchange). Tracheostomy was performed in 91% of patients. Mortality was higher in older patients (41 vs. 7%; p = 0.02) and overall outcome worse (p = 0.05). Interestingly, once surviving the early, most critical period, older patients functionally recovered as well as younger patients (80% good outcome vs. 86%; p = 0.71). CONCLUSIONS: Despite all the advances in intensive care, mortality in older, ventilated GBS patients is still substantial. However, once they have survived the early, most critical period, older patients may recover as well as younger patients. Special care should therefore be taken to prevent and, if present, to vigorously treat complications commonly associated with intensive care treatment of severe GBS in elderly patients.

Request full text

Posted in Ward Round Update | Leave a comment

Carbapenem-resistant Acinetobacter baumannii (CRAB) infection

Please find below some reading on carbapenem-resistant Acinetobacter baumannii (CRAB) infections.

Please note that inclusion in this blog is not an endorsement of quality.

Please follow local protocols for drug doses.

To access full text you will need an NHS OpenAthens account. Please sign up here if you haven’t already got one.

KnowledgeShare is a current awareness tool which helps you deal with information overload, while ensuring that you receive high quality information on topics that are important to you. Take five minutes to fill in this form and we will send you regular updates on your chosen topic.

Guidance

Infections Diseases Society of America (2026) IDSA Guidance on the Treatment of Antimicrobial Resistant Gram-Negative Infections – Section 5: Carbapenem-resistant Acinetobacter baumannii complex (CRAB)

European Society of Clinical Microbiology and Infectious Diseases (2022) ESCMID guidelines for the treatment of infections caused by multidrug-resistant Gram-negative bacilli (endorsed by European Society of Intensive Care Medicine)

DynaMed

DynaMed (2026) Bacteremia With Gram-negative Bacilli

Articles

1. Acinetobacter

Authors: Bento, Diogo and Tobin, Ellis H.
Publication Date: 2026
Journal: StatPearls

Abstract: Acinetobacter species are ubiquitous in nature and may be isolated from soil, water, commercial food products, hospital environmental surfaces, and medical devices. The organism demonstrates remarkable persistence under adverse conditions, including disinfection and desiccation. In humans, Acinetobacter may transiently colonize the skin, respiratory tract, and gastrointestinal tract, particularly in hospital settings. Frequent colonization complicates assessment of clinical significance and decisions regarding antimicrobial therapy. Although Acinetobacter generally exhibits low intrinsic virulence, it can cause severe infections in patients with immunodeficiency, neutropenia, or critical illness. Reported diseases include pneumonia and wound, surgical site, bloodstream, and urinary tract infections, often associated with invasive procedures and indwelling medical devices. Most cases result from nosocomial transmission rather than community acquisition, highlighting the importance of rigorous infection prevention and control measures in healthcare facilities. Antibiotic resistance further limits therapeutic options and increases morbidity and mortality. Due to high mortality and constrained antimicrobial choices, the Centers for Disease Control and Prevention (CDC) and the World Health Organization classify carbapenem-resistant Acinetobacter baumannii (CRAB) as a priority 1 critical pathogen.

Access full text

2. Risk factors for carbapenem-resistant Acinetobacter baumannii (CRAB) infections in critically ill patients with previous CRAB colonization: a multicentre cohort study

Authors: Cogliati Dezza, Francesco; Gutiérrez-Gutiérrez, Belén; Tiseo, Giusy, et al
Publication Date: 2026
Journal: JAC-Antimicrobial Resistance 8(1), pp.dlaf262

Abstract: BACKGROUND: Among MDR bacteria, carbapenem-resistant Acinetobacter baumannii (CRAB) is a major concern due to the limited therapeutic options. OBJECTIVES: To identify predictors to aid in the clinical management of critically ill patients. METHODS: We conducted a multicentre prospective study in Italy, enrolling patients with CRAB colonization who were admitted to ICUs between 2020 and 2023. Multivariable logistic regression analysis was performed to identify potential risk factors for CRAB infection. To account for competing risks, we used the cumulative incidence function (CIF) and Fine-Gray regression analysis, providing an accurate assessment of the risk of CRAB infection. Additionally, a logistic regression model was performed to estimate the impact of different types of critically ill patients on the risk of infection. RESULTS: We included 564 colonized patients, and 381 (67.5%) developed a CRAB infection in the ICU. In the logistic regression model, multisite colonization (OR 2.78; 95% CI: 1.90-4.08; P < 0.001), Charlson comorbidity index (CCI) ≥3 (OR 1.59; 95% CI: 1.00-2.50; P = 0.047), mechanical ventilation (OR 1.48; 95% CI: 1.00-2.18; P = 0.048), male gender (OR 2.06; 95% CI: 1.38-3.10; P < 0.001), and time from ICU admission to colonization ≤12 days (OR 2.00; 95% CI: 1.36-2.94; P < 0.001) were independent predictors of CRAB infection. Findings were confirmed in the Fine-Gray model. In a secondary model, COVID-19 (OR 2.31; 95% CI: 1.30-4.10; P = 0.004) and burn patients (OR 4.84; 95% CI: 1.65-14.17; P = 0.004) were risk factors for CRAB infection. CONCLUSIONS: Early colonization from ICU admission, multisite colonization, CCI, mechanical ventilation and male gender are key risk factors for CRAB infection. These factors support clinicians in the management of critically ill patients with prior CRAB colonization.

Access full text

3. From high-touch surfaces to air: A prospective genomic analysis unveils an underestimated transmission route of carbapenem-resistant Acinetobacter baumannii in the ICU

Authors: Ding, Honghui; Miao, Yu; Sun, Ling, et al
Publication Date: 2026
Journal: International Journal of Infectious Diseases : IJID : Official Publication of the International Society for Infectious Diseases 168, pp.108718

Abstract: OBJECTIVES: To investigate the extent of environmental contamination around carbapenem-resistant Acinetobacter baumannii (CRAB)-positive patients and to explore the role of environmental factors in the pathogen’s transmission dynamics. METHODS: Prospectively collected CRAB-positive specimens from intensive care unit (ICU) patients and their immediate environments from September 2024 to April 2025. Positive detection rates were quantified and statistical analyzed by sample type, and whole-genome sequencing (WGS) was employed to determine phylogenetic relationships and evolutionary dynamics among the isolates. RESULT: The overall environmental positivity rate in patient bed units was 13.08%, significantly higher than in other public areas (P < 0.001). High-touch surfaces (HTS) and air sampling sites samples showed markedly higher positivity rates compared to healthcare worker-related sites (HWS) samples (P < 0.001). HTS sample with direct patient or body fluid contact exhibited higher bacterial loads (HR = 1.623, 95% CI 1.178-2.237, P = 0.03), and HWS samples yielded similar findings (HR = 2.325, 95% CI 1.167-4.632, P = 0.016) for HWS), while air samples demonstrated distinct growth kinetics. WGS analysis identified ST2 as the predominant strain, while airborne isolates displayed greater genetic diversity than HTS isolates (P = 0.013), and we successfully reconstructed two potential transmission events. CONCLUSION: The airborne transmission route of CRAB has been substantially underestimated, necessitating the urgent implementation of additional infection control measures to limit its spread within ICUs.

Access full text

4. Infection Control Strategies to Prevent Emergence and Transmission of Resistant Gram-Negative Bacteria

Authors: Mills, John P.; Rogozin, Evgeny; Seok, Hyeri, et al
Publication Date: 2026
Journal: Infectious Disease Clinics of North America 40(3), pp.621–639

Abstract: Multidrug-resistant gram-negative bacteria pose a major threat to patient safety, driven by efficient transmission within health care settings and increasing antimicrobial resistance. This review synthesizes current epidemiology, key reservoirs, and evidence-based prevention strategies for extended-spectrum β-lactamase-producing Enterobacterales, carbapenem-resistant Enterobacterales, carbapenem-resistant Pseudomonas aeruginosa , and carbapenem-resistant Acinetobacter baumannii. Core interventions include hand hygiene, targeted contact precautions, optimized environmental cleaning, and antimicrobial stewardship. Active surveillance and patient cohorting have selective roles depending on the specific organism, setting, and endemicity. Emerging tools, such as whole-genome sequencing, better delineate transmission dynamics to guide outbreak response.

Request full text

5. Site-specific and time-varying Acinetobacter colonization and risk of invasive infection in critically ill patients

Authors: Russo, Alessandro; Gullì, Sara Palma; Garofalo, Eugenio, et al
Publication Date: 2026
Journal: Infection 54(4), pp.2033–2040

Abstract: PURPOSE: Colonization by Acinetobacter baumannii is common among critically ill patients. However, the relative contribution of colonization at different anatomical sites and the impact of dynamic changes in colonization status over time remain incompletely defined. METHODS: We conducted a retrospective cohort study of adult intensive care unit (ICU) patients with at least one surveillance culture positive for carbapenem-resistant Acinetobacter spp. (CRAB) between January 2022 and January 2026. Active surveillance cultures were obtained at ICU admission and weekly thereafter from respiratory, rectal, and skin sites. Progression to invasive CRAB infection (pneumonia and/or bloodstream infection) was assessed using multivariable logistic regression and Cox proportional hazards models with site-specific, time-updated colonization as exposures. Sensitivity analyses excluded infections occurring within 72 h of ICU admission. RESULTS: Among 489 colonized ICU patients, 313 (64.0%) progressed to invasive CRAB infection during ICU stay. Respiratory colonization at ICU admission was strongly associated with progression to infection (adjusted OR, 5.46; 95% CI, 3.18-9.37), whereas rectal colonization was not independently associated with risk. In time-updated Cox models, respiratory (adjusted HR, 1.72; 95% CI, 1.35-2.18) and skin colonization (adjusted HR, 1.65; 95% CI, 1.31-2.08) were independently associated with infection risk. Colonization at multiple anatomical sites conferred additional risk. CONCLUSIONS: Progression to invasive infection was common and strongly associated with site-specific and time-varying colonization patterns, particularly involving the respiratory tract. Incorporating dynamic, multisite colonization data into risk assessment may improve identification of patients at highest risk for invasive infection and inform targeted infection prevention strategies in the ICU.

Access full text

6. Predictors of mortality and therapeutic efficacy in carbapenem-resistant Acinetobacter baumannii bacteremia

Authors: Russo, Alessandro; Gullì, Sara Palma; Vena, Antonio, et al
Publication Date: 2026
Journal: The Journal of Infection 92(5), pp.106742

Abstract: OBJECTIVES: Bacteremia caused by carbapenem-resistant Acinetobacter baumannii (CRAB) is associated with high morbidity and mortality. The primary objective was to identify clinical and therapeutic factors associated with 14- and 30-day mortality following infection onset. METHODS: This was a prospective, observational, multicenter study conducted across 52 Italian centers. Over an 18-month period, adult hospitalized patients with CRAB bacteremia were enrolled. RESULTS: Among 398 patients with CRAB bacteremia, sources were mainly CVC-related or primary, with 14- and 30-day mortality rates of 22% and 27% respectively. Cox regression analysis identified male sex (p=0.006), and chronic kidney disease (p=0.016) as independent predictors of 14-day mortality, while colistin-containing regimen (p=0.014), and cefiderocol-containing-regimen (p<0.001) were associated with 14-day survival; male sex (p=0.027), septic shock (p=0.018), previous colonization by A. baumannii (p<0.001), and tigecycline-containing regimen (p=0.021) were independent predictors of 30-day mortality, while cefiderocol-containing-regimen (p<0.001) was associated with 30-day survival. Propensity score matching revealed that cefiderocol was significantly associated with 14-day survival and clinical success. The combination of cefiderocol plus Fosfomycin was also significantly associated with clinical success. CONCLUSION: Our findings highlight key clinical and therapeutic determinants of mortality and survival in patients with CRAB bacteraemia, providing valuable insights for improving the management of this challenging infection.

Access full text

7. Carbapenem-resistant Acinetobacter baumannii infections in intensive care units: incidence, infection prevention and control, and antimicrobial stewardship practices in the cross-border region between Italy and France, 2019-2022

Authors: Vicentini, C.; Bussolino, R.; Kuczewski, E., et al
Publication Date: 2026
Journal: The Journal of Hospital Infection 170, pp.174–183

Abstract: BACKGROUND: Carbapenem-resistant Acinetobacter baumannii (CRAB) is a priority-1 critical pathogen with limited treatment options and high mortality among intensive care unit (ICU) patients. Italy reports hyperendemic levels, whereas France maintains low prevalence. Understanding cross-border differences is essential to inform infection prevention and control (IPC) and antibiotic stewardship strategies. AIM: We investigated incidence trends of CRAB infections in ICUs across the French-Italian border and assessed structural, organizational, IPC, and stewardship practices to identify factors associated with infection risk. METHODS: We conducted a multi-centre observational study involving ICUs of four cross-border regions (Piemonte, Valle d’Aosta, Auvergne-Rhône-Alpes, and Provence-Alpes-Côte d’Azur). Data on ICU-acquired bloodstream infections (BSI), central-line-associated BSI, pneumonia, and ventilator-associated pneumonia with CRAB isolates were extracted from the GiViTI and Réa-Rézo surveillance systems (2019-2022). A structured survey explored ICU characteristics, IPC, and stewardship practices. Logistic regression analysis was performed to identify factors associated with CRAB infection episodes. RESULTS: Overall, 25 ICUs participated in data collection. Among 24,822 ICU admissions, the proportion of A. baumannii isolates that were carbapenem resistant was 18.75% (95% confidence interval [CI]: 7.97-34.98) in France and 83.56% (95% CI: 80.1-86.63) in Italy. Different approaches to IPC and antibiotic stewardship were highlighted. Structural ICU design, staffing flexibility, and resilient IPC and stewardship practices were associated with lower infection risk. CONCLUSION: The CRAB incidence was substantially higher in Italy than in France. Cross-border harmonization of surveillance and co-ordinated preventive strategies are critical to contain cross-border spread.

Access full text

8. Drug-resistant Acinetobacter baumannii: mortality, emerging treatments, and future pharmacological targets for a WHO priority pathogen

Authors: Dubey, Vineet; Reza, Nada and Hope, William
Publication Date: 2025
Journal: Clinical Microbiology Reviews 38(3), pp.e0027924–24. Epub 2025 Aug 11

Abstract: SUMMARYAcinetobacter baumannii has emerged as a formidable global health concern and is a major contributor to infection-related mortality in critically ill patients worldwide. This versatile Gram-negative bacterium is notorious for its highly plastic genome, which enables the rapid emergence and dissemination of multidrug-resistant (MDR) and extensively drug-resistant (XDR) strains, severely limiting the available treatment options. The genetic flexibility of A. baumannii underpins its arsenal of molecular mechanisms, enabling it to resist a range of antibiotics, from traditional agents to the latest therapeutic advancements available. With the progress made in treatments against Acinetobacter infections and various drugs undergoing clinical trials, the effectiveness of these treatments is often outpaced by the pathogen’s swift evolution of resistance, resulting in alarmingly high rates of treatment failure. In this systematic review of literature spanning 2004-2024, we highlight the high mortality rates associated with infections caused by XDR strains and carbapenem-resistant A. baumannii (CRAB). This review provides a comprehensive examination of the resistance mechanisms deployed by A. baumannii, encompassing both conventional antibiotics and novel agents used in global healthcare settings. In addition, we discuss emerging druggable targets and the inherent challenges in their development, offering strategic insights into next-generation therapeutic programs. A deep profound understanding of the pathogen’s molecular defenses is essential to guide the design of innovative therapies aimed at mitigating the escalating threat posed by A. baumannii.

Access full text

9. Environmental contamination of carbapenem-resistant gram-negative bacteria away from isolated patients in intensive care unit: a comprehensive surveillance study

Authors: Xiao, Pan; Huang, Hui-Chao; Li, Chen, et al
Publication Date: 2025
Journal: Scientific Reports 16(1), pp.680–2

Abstract: Environmental contamination by carbapenem-resistant gram-negative bacteria (CR-GNB) contributes to healthcare-associated infections in intensive care unit (ICU). However, contamination in areas away from isolated patients remains inadequately characterized, and local epidemiological data are limited. A comprehensive surveillance study was conducted in the ICU of a tertiary hospital from January 2019 to December 2022. Monthly collections included clinical specimens (sputum, urine, blood) and environmental samples (inanimate surfaces, healthcare workers’ hands). Gram-negative bacteria were cultured, and carbapenem sensitivity testing was performed. Among 5,097 clinical specimens collected over the 4-year study period, 898 (17.6%) GNB isolates and 405 (8.0%) CR-GNB isolates were detected, with Klebsiella pneumoniae and carbapenem-resistant Acinetobacter baumannii (CRAB) being the most common species. From 2,215 environmental samples, 144 (6.5%) GNB and 90 (4.1%) CR-GNB strains were identified, predominantly A. baumannii and CRAB. The overall CR-GNB environmental contamination rates were highest on work coats (6.8%), followed by nonisolated patient medical devices (5.8%), nonisolated patient bed units (4.3%), mobile phones (4.1%), doctors’ offices and nurses’ stations (3.6%), and healthcare workers’ hands (2.0%). Spearman’s correlation analysis revealed a significant positive correlation between the monthly number of positive A. baumannii or CRAB isolates from environmental samples and clinical specimens. CR-GNB, particularly CRAB, contaminates ICU environments, including nonisolated patient areas and healthcare stations, highlighting the need for enhanced environmental surveillance in the ICU.

Access full text

10. Acinetobacter baumannii in the critically ill: complex infections get complicated

Authors: Cavallo, Ilaria; Oliva, Alessandra; Pages, Rebecca, et al
Publication Date: 2023
Journal: Frontiers in Microbiology 14, pp.1196774

Abstract: Acinetobacter baumannii is increasingly associated with various epidemics, representing a serious concern due to the broad level of antimicrobial resistance and clinical manifestations. During the last decades, A. baumannii has emerged as a major pathogen in vulnerable and critically ill patients. Bacteremia, pneumonia, urinary tract, and skin and soft tissue infections are the most common presentations of A. baumannii, with attributable mortality rates approaching 35%. Carbapenems have been considered the first choice to treat A. baumannii infections. However, due to the widespread prevalence of carbapenem-resistant A. baumannii (CRAB), colistin represents the main therapeutic option, while the role of the new siderophore cephalosporin cefiderocol still needs to be ascertained. Furthermore, high clinical failure rates have been reported for colistin monotherapy when used to treat CRAB infections. Thus, the most effective antibiotic combination remains disputed. In addition to its ability to develop antibiotic resistance, A. baumannii is also known to form biofilm on medical devices, including central venous catheters or endotracheal tubes. Thus, the worrisome spread of biofilm-producing strains in multidrug-resistant populations of A. baumannii poses a significant treatment challenge. This review provides an updated account of antimicrobial resistance patterns and biofilm-mediated tolerance in A. baumannii infections with a special focus on fragile and critically ill patients.

Access full text

Posted in Ward Round Update | Leave a comment

Tuberculosis medication

Following ward round on 10 September, please find below some further information on tuberculosis medication.

Please note that inclusion in this blog is not an endorsement of quality.

Please follow local protocols for drug doses.

To access full text you will need an NHS OpenAthens account. Please sign up here if you haven’t already got one.

KnowledgeShare is a current awareness tool which helps you deal with information overload, while ensuring that you receive high quality information on topics that are important to you. Take five minutes to fill in this form and we will send you regular updates on your chosen topic.

Guidance

BNF (2026) Tuberculosis

NICE (2024) Tuberculosis

WHO (2025) WHO consolidated guidelines on tuberculosis: module 4: treatment and care

BMJ Best Practice (2026) Pulmonary tuberculosis

BMJ Best Practice (2026) Extrapulmonary tuberculosis

Articles

1. Advances in tuberculosis treatment: novel regimens, new drug pipelines, host-directed therapies, and updated management guidelines

Authors: Marais, Ben J.; Goletti, Delia; McHugh, Timothy D., et al
Publication Date: 2027
Journal: The Lancet.Microbe , pp.101442

Abstract: Tuberculosis treatment has undergone its most profound transformation since the launch of the standardised DOTS strategy in 1994. Since 2020, a series of pivotal randomised trials, including TB-PRACTECAL, ZeNix, Nix-TB, endTB, BEAT-TB, SHINE, and Study 31/A5349, have redefined the management of both drug-susceptible and drug-resistant tuberculosis. These studies have enabled shorter, fully oral regimens with improved efficacy and safety across adult and paediatric populations, including people with HIV, and have driven major updates to WHO treatment guidelines. Despite these advances, tuberculosis remains the leading cause of death from a single infectious agent worldwide, with substantial mortality occurring before treatment initiation due to delayed diagnosis and pretreatment loss to follow-up, and additional deaths during treatment related to advanced disease, drug resistance, comorbidities, and challenges with treatment tolerance and adherence. In 2024, an estimated 10·7 million people developed tuberculosis of whom approximately 390 000 developed multidrug-resistant (MDR) or rifampicin-resistant (RR) tuberculosis. Tuberculosis caused an estimated 1·23 million deaths globally, including approximately 150 000 deaths attributable to MDR tuberculosis or RR tuberculosis. Outcomes remain poorest among people with HIV, young children (who rarely access treatment and prevention), migrants, and displaced populations. The tuberculosis drug development pipeline in 2026 is more advanced than at any time since the introduction of rifampicin. Novel and repurposed compounds, including DprE1 inhibitors, next-generation oxazolidinones (including TBAJ-587 and TBAJ-876), cytochrome bc1 inhibitors, and long-acting formulations, are in late-stage evaluation. Host-directed therapies are also advancing as adjunctive strategies to reduce inflammation-mediated tissue damage and long-term morbidity, although they remain investigational. This Series paper synthesises advances in adult and paediatric tuberculosis therapeutics from Nov 15, 2020, to Jan 15, 2026, and highlights priorities to translate therapeutic innovation into equitable population-level effects.

Access full text

2. Implementing shorter all-oral treatment durations for multidrug-resistant tuberculosis in the UK: from concept to application

Authors: Chavda, Aneeka; Gilchrist, Mark; Capstick, Toby, et al
Publication Date: 2026
Journal: BMJ Open Respiratory Research 13(1), pp.e003861. doi: 10.1136/bmjresp–003861

Abstract: Multidrug-resistant tuberculosis (MDR-TB) is a global public health threat associated with high mortality and challenging treatment regimens. The UK, like many countries, faces a growing incidence of MDR-TB, with 105 (1.9% of all notified cases) treated as MDR-resistant or rifampicin-resistant TB in 2024. Recent clinical trials have demonstrated the efficacy and safety of shorter, all-oral regimens such as BPaLM (bedaquiline, pretomanid, linezolid, moxifloxacin), yet their implementation in the UK presents unique challenges, particularly around the antimicrobial stewardship (AMS) agenda, such as the lack of licensed drugs, pharmacokinetic/dynamic concerns, fragile supply chains and high cost of second-line antituberculosis drugs. This narrative review outlines how the UK has addressed implementation hurdles through coordinated efforts by the British Thoracic Society MDR-TB Clinical Advice Service and National Health Service England. This collaboration has facilitated the adoption of new regimens, with 54 out of 60 requests for using pretomanid-containing regimens approved in the UK up to January 2026. Furthermore, resources like the TB Drug Monographs and the shift to video-observed therapy have streamlined care delivery. The UK has effectively navigated the transition to shorter, all-oral MDR-TB regimens, significantly enhancing patient care and operational efficiency. The integration of clinical guidance, AMS principles, policy reform and specialised monitoring tools provides a robust framework for managing evolving treatment landscapes and delivering patient-centred care.

Access full text

3. Current and emerging therapies for pulmonary tuberculosis in adults

Authors: Mahmood, Amira; Ashfaq, Mohammad Bilal; Drain, Catherine, et al
Publication Date: 2026
Journal: BMJ Medicine 5(1), pp.e001836–001836. eCollection 2026

Abstract: Tuberculosis remains the biggest global killer from infectious causes, with an estimated 1.25 million deaths per year. The quadruple drug regimen of rifampicin, isoniazid, pyrazinamide, and ethambutol has been standard therapy for 40 years, with good outcomes in patients with drug susceptible tuberculosis who are able to tolerate the drug regimen. However, the frequency of adverse drug reactions and emergence of drug resistant tuberculosis has created demand for new treatment strategies: there is now a surge in novel tuberculosis agents and regimens entering human trials. For decades, drug resistant tuberculosis required at least 18 months of second line and third line combination treatments that included injectable agents. In 2022, in response to a growing body of trial evidence, the World Health Organization (WHO) introduced six month and nine month all oral regimens for pulmonary drug resistant tuberculosis in specific settings. These encompass agents in the bedaquiline-pretomanid-linezolid/moxifloxacin regimen, as well as repurposed and novel agents such as clofazimine and delamanid. In addition, a large number of novel antimicrobial and host directed treatments are progressing to late stage clinical trials for tuberculosis, raising the prospect of shorter, more efficacious, and better tolerated treatments. This review summarises the agents and regimens recommended in the latest consolidated WHO treatment guidelines for tuberculosis (2025), including a synopsis of the evidence base for their safety, efficacy, and cost effectiveness. It also outlines the antimicrobial and host directed treatments that have entered phase 2-4 clinical trials for pulmonary tuberculosis in adults.

Access full text

4. Drug management of TB in the intensive care setting: an international multicentre study

Authors: Tiberi, S.; Akkerman, O.; Sotgiu, G., et al
Publication Date: 2025
Journal: The International Journal of Tuberculosis and Lung Disease : The Official Journal of the International Union Against Tuberculosis and Lung Disease 29(8), pp.340–348

Abstract: BACKGROUNDIndividuals requiring admission to an intensive care unit (ICU) due to TB have complex clinical presentations and high mortality rates. There is a clear knowledge gap on how to optimally manage treatment.OBJECTIVETo evaluate the treatment outcomes of TB patients in ICU and explore the potential benefits of intravenous (IV) TB treatment regimens.METHODSA retrospective observational multicentre study was conducted by the International Severe TB and Rehabilitation Working Group of the Global Tuberculosis Network (GTN). The study included TB patients aged >15 years admitted to ICUs in Europe, Asia and Latin America from January 1, 2005 to December 31, 2018. Data on demographics, microbiology, clinical information and treatment outcomes were collected and analysed.RESULTSThe study enrolled 434 cases. Over half were sputum smear-positive and 85.7% were culture-positive. Most required invasive mechanical ventilation, vasopressor support and steroids. Only 48.4% had TB medications initiated before or during ICU admission. The overall mortality rate was 54.8%, with 33.4% achieving treatment success. IV anti-TB drugs were administered to 43% of participants, with levofloxacin and amikacin being the most used. IV treatment longer than 10 days was associated with better outcomes. Individuals receiving IV rifampicin had a lower mortality rate (35.7%) compared to those who did not receive it (51.7%), p-value= 0.05.CONCLUSIONSHigh mortality rates in ICU indicate the need for improved management strategies. The use of IV TB drugs, especially IV rifampicin, show potential benefit, suggesting the need for further prospective studies. Early screening and standardized treatment protocols could improve patient outcomes in high-incidence areas..

Request full text

5. Tuberculosis

Authors: Trajman, Anete; Campbell, Jonathon R.; Kunor, Tenzin, et al
Publication Date: 2025
Journal: Lancet (London, England) 405(10481), pp.850–866

Abstract: Tuberculosis is a leading cause of death globally. Given the airborne transmission of tuberculosis, anybody can be infected, but people in high-incidence settings are more exposed. Risk of progression to disease is higher in the first years after infection, and in people with undernourishment, immunosuppression, or who smoke, drink alcohol, or have diabetes. Although cough, fever, and weight loss are hallmark symptoms, people with tuberculosis can be asymptomatic, so a high index of suspicion is required. Prompt diagnosis can be made by sputum examination (ideally with rapid molecular tests), but chest radiography can be helpful. Most people with disease can be treated with regimens of 6 months or less; longer regimens may be necessary for those with drug resistance. Central to successful treatment is comprehensive, person-centred care including addressing key determinants, such as undernourishment, smoking, and alcohol use, and optimising management of comorbidities, such as diabetes and HIV. Care should continue after treatment ends, as long-term sequelae are common. Prevention relies mostly on treatment with rifamycin-based regimens; current vaccines have limited efficacy. Ongoing research on shorter and safer regimens for infection and disease treatment, and simpler and more accurate diagnostic methods will be key for tuberculosis elimination.

Request full text

6. Recent advances in the treatment of tuberculosis

Authors: Motta, Ilaria; Boeree, Martin; Chesov, Dumitru, et al
Publication Date: 2024
Journal: Clinical Microbiology and Infection : The Official Publication of the European Society of Clinical Microbiology and Infectious Diseases 30(9), pp.1107–1114

Abstract: BACKGROUND: Tuberculosis (TB) is a global health challenge and one of the leading causes of death worldwide. In the last decade, the TB treatment landscape has dramatically changed. After long years of stagnation, new compounds entered the market (bedaquiline, delamanid, and pretomanid) and phase III clinical trials have shown promising results towards shortening duration of treatment for both drug-susceptible (Study 31/A5349, TRUNCATE-TB, and SHINE) and drug-resistant TB (STREAM, NiX-TB, ZeNix, and TB-PRACTECAL). Dose optimization of rifamycins and repurposed drugs has also brought hopes of further development of safe and effective regimens. Consequently, international and WHO clinical guidelines have been updated multiple times in the last years to keep pace with these advances. OBJECTIVES: This narrative review aims to summarize the state-of-the-art on treatment of drug-susceptible and drug-resistant TB, as well as recent trial results and an overview of ongoing clinical trials. SOURCES: A non-systematic literature review was conducted in PubMed and MEDLINE, focusing on the treatment of TB. Ongoing clinical trials were listed according to the authors’ knowledge and completed consulting clinicaltrials.gov and other publicly available websites (www.resisttb.org/clinical-trials-progress-report, www.newtbdrugs.org/pipeline/trials). CONTENT: This review summarizes the recent, major changes in the landscape for drug-susceptible and drug-resistant treatment, with a specific focus on their potential impact on patient outcomes and programmatic TB management. Moreover, insights in host-directed therapies, and advances in pharmacokinetics and pharmacogenomics are discussed. A thorough outline of ongoing therapeutic clinical trials is presented, highlighting different approaches and goals in current TB clinical research. IMPLICATIONS: Future research should be directed to individualize regimens and protect these recent breakthroughs by preventing and identifying the selection of drug resistance and providing widespread, affordable, patient-centred access to new treatment options for all people affected by TB.

Access full text

Posted in Ward Round Update | Leave a comment

Carotid endarterectomy

Following ward round on 10 September, please find below some further reading on carotid endarterectomy.

Please note that inclusion in this blog is not an endorsement of quality.

Please follow local protocols for drug doses.

To access full text you will need an NHS OpenAthens account. Please sign up here if you haven’t already got one.

KnowledgeShare is a current awareness tool which helps you deal with information overload, while ensuring that you receive high quality information on topics that are important to you. Take five minutes to fill in this form and we will send you regular updates on your chosen topic.

DynaMed

DynaMed (2026) Carotid Revascularization See especially the sections on Carotid Endarterectomy-Related Considerations and Complications of Carotid Endarterectomy

BMJ Best Practice

BMJ Best Practice (2026) Carotid artery stenosis

Articles

1. Comparative safety and efficacy of invasive therapies for carotid artery stenosis: a systematic review and network meta-analysis

Authors: Amran, Muhammad Yunus; Fitrah, Yusran Ady; Larassaphira, Nabilah Puteri, et al
Publication Date: 2026
Journal: Journal of Neurointerventional Surgery 18(6), pp.1545–1557

Abstract: BACKGROUND: Carotid artery stenosis is a major cause of stroke and is commonly treated with carotid endarterectomy (CEA) or carotid artery stenting (CAS). Trans-carotid artery revascularization (TCAR) has emerged as a newer alternative designed to reduce the risk of procedural stroke. However, comparative evidence on the safety and efficacy of these interventions is limited. This study evaluates the clinical outcomes of CEA, CAS, and TCAR in patients with carotid artery stenosis. METHODS: A comprehensive search of multiple databases was conducted to identify relevant studies. The outcomes were stroke, mortality, and myocardial infarction, cranial nerve injury, hematoma, infection, transient ischemic attack, and length of hospital stay. Meta-analysis and a frequentist graph-theoretical approach network meta-analysis were performed using the netmeta package in R platform. Risk of bias was assessed using RoB 2 Cochrane and ROBINS-I. RESULTS: Fifty-five studies were included in the review. The short-term stroke risk was significantly lower with CEA than with CAS. TCAR had a potential long-term mortality benefit over CAS, while no significant differences were observed in short-term mortality or myocardial infarction across treatments. CAS was associated with lower risks of cranial nerve injury, hematoma, and infection compared with CEA. CONCLUSION: CEA and TCAR offer better short-term stroke protection than CAS, with TCAR showing promise for long-term mortality benefits. CAS has advantages in reducing cranial nerve injury, hematoma, and infection risks. Overall, the choice of treatment should consider both efficacy and safety profiles. Further high-quality randomized controlled trials, particularly focusing on TCAR, are needed to validate these comparative outcomes. PROSPERO REGISTRY NUMBER: CRD420251055287.

Access full text 

2. Carotid Endarterectomy

Authors: DaCosta, Mary; Tadi, Prasanna and Surowiec, Scott M.
Publication Date: 2026
Journal: StatPearls

Abstract: A buildup of plaque in the carotid artery can lead to atherosclerosis and stenosis of the artery, which may or may not be symptomatic clinically. Such carotid artery disease increases a person’s risk for cerebrovascular disease and stroke. Carotid endarterectomy (CEA) is a surgery performed to decrease the risk of stroke in a patient with known cerebrovascular atherosclerotic disease. The procedure entails removing plaque from the common carotid artery and/or internal carotid artery to improve blood flow and remove potential embolic material, restoring more normal cerebral blood flow. Carotid artery reconstructions began in the early 1950s, and techniques for carotid endarterectomy procedures, as well as indications to perform them, have evolved.

Access full text

3. Carotid artery stenosis: a guide for clinicians

Authors: Namjouyan, Kamran; Tangsrivimol, Jonathan A.; Rizwan, Affan, et al
Publication Date: 2026
Journal: Future Cardiology 22(6), pp.621–631

Abstract: Carotid artery stenosis (CS) is a critical diagnosis linked to ischemic stroke, a leading cause of morbidity and mortality, affecting about 4% of the general population. Risk factors for CS include age, hypertension, dyslipidemia, diabetes, and smoking, with poly vascular disease seen in 45% of patients with known atherosclerotic disease. Early recognition and management of CS are crucial to prevent stroke by utilizing imaging modalities like Duplex ultrasound (DUS). Management of CS involves complex decision-making that balances the risks and benefits of intervention against the developing diagnostic and therapeutic modalities. This narrative review aims to review and examine the current guidelines for clinicians’ approach to CS.

Access full text

4. The diagnosis and treatment of asymptomatic and symptomatic patients with carotid artery stenosis

Authors: Henning, Robert J. and Hoh, Brian L.
Publication Date: 2025
Journal: Current Problems in Cardiology 50(6), pp.102992

Abstract: Carotid artery atherosclerotic stenosis is an important annual cause of stroke in the United States. Moreover, the incidence of carotid artery stenosis is significantly increasing due to the widespread popularity of high fat and high salt diets, sedentary lifestyles, and the increasing age of the population. Of major importance to cardiovascular specialists is the fact that individuals with atherosclerotic carotid artery stenosis can have a prevalence of atherosclerotic coronary artery disease as high as 50 to 75%. Vascular screening for carotid artery stenosis with Doppler ultrasound should be considered for all symptomatic patients with possible carotid stenosis and also considered for asymptomatic patients with (1) symptomatic peripheral arterial disease, coronary artery disease, or atherosclerotic aortic aneurysm or, (2) multiple atherosclerotic risk factors. Carotid artery atherosclerotic plaques that are at high risk for rupture and thrombosis or cerebral embolization are characterized by large lipid cores, intraplaque hemorrhage, thin fibrous caps less than 165 μms that are infiltrated by macrophages and T cells or have surface ulcer(s) or fissures. Carotid artery plaque rupture with cerebral embolism can cause a stroke, transient ischemic attacks (TIA), or ipsilateral blindness (amaurosis fugax). Medical treatment based on the recommendations of the American and European Societies for Vascular Surgery and the American Heart Association for symptomatic patients with carotid stenosis and also asymptomatic patients with high risk carotid stenosis plaques include antiplatelet drugs, antihypertensive drugs for hypertension control and lipid lowering drugs. Management strategies and decisions about carotid revascularization in asymptomatic patients with high risk carotid stenosis should involve a multidisciplinary team and shared decision-making is recommended. The 30 day and five to 10 year outcomes in asymptomatic carotid stenosis patients who have undergone carotid endarterectomy, carotid stenting and/or optimal medical therapy are summarized from the Veterans Administration Cooperative Study, the Asymptomatic Carotid Atherosclerosis Study and the Asymptomatic Carotid Surgery Trials. The current Carotid Revascularization and Medical Management for Asymptomatic Carotid Stenosis Trial (CREST-2) should help to resolve the debate regarding carotid artery revascularization versus primary medical treatment in asymptomatic patients with >70% carotid artery stenosis. Symptomatic patients who present within 4.5 hours of stroke onset require evaluation for acute intravenous pharmacologic thrombolysis and patients who present with large vessel occlusion within 24 hours of symptom onset should be considered for mechanical thrombectomy to reduce the neurologic deficit. Patients with carotid artery stenosis who present with a history of cerebral infarct in the preceding six months due to cerebral embolism require medical treatment and evaluation by a multidisciplinary team for carotid revascularization in order to prevent future strokes or TIAs. The outcomes of the North American Symptomatic Carotid Endarterectomy Trial, Carotid Revascularization Endarterectomy Versus Stent Trial, Stent-Supported Percutaneous Angioplasty of the Carotid Artery vs. Endarterectomy Trial, and the Safety and Efficacy Study for Reverse Flow Used during Carotid Artery Stenting Procedure trials for symptomatic patients with carotid stenosis are reviewed. A synopsis of treatment guidelines for symptomatic and asymptomatic carotid stenosis patients from the American and European Societies of Vascular Surgery and the American Heart Association/American Stroke Association are presented. Each patient with carotid artery stenosis must be carefully evaluated to determine the best treatment based on the clinical presentation, the imaging and laboratory diagnostic information, the treatment guidelines, and the patient needs and preferences as well as the patient’s social and cultural factors.

Request full text

5. Seizures Following Carotid Endarterectomy: A Comprehensive Meta-Analysis of 69,479 Patients and Evidence-Based Recommendations for Perioperative Care

Authors: Rajesh, Kruthajn; Shen, Helen and Bhaskar, Sonu M. M.
Publication Date: 2024
Journal: Diagnostics (Basel, Switzerland) 15(1), pp.6. doi: 10.3390/diagnostics15010006

Abstract: Background: Seizures are a rare but potentially serious complication following carotid endarterectomy (CEA). Understanding their prevalence and associated factors is crucial for optimizing perioperative care and improving patient outcomes. This meta-analysis aimed to estimate the pooled prevalence of seizures following CEA and explore clinical and procedural factors contributing to their occurrence. Methods: We conducted a systematic review and meta-analysis of studies reporting on seizures following CEA. A systematic search of PubMed, Embase, and Cochrane CENTRAL databases was performed, following PRISMA and MOOSE guidelines. Random-effects meta-analysis was used to calculate the pooled prevalence of postoperative seizures. Heterogeneity was assessed using the I(2) statistic. A total of 20 studies, encompassing 69,479 patients, were included. Results: The overall pooled prevalence of seizures following CEA was 1% (95% CI: 0-2%; p < 0.001), with significant heterogeneity (I(2) = 93.52%). Prospective studies reported a higher pooled prevalence (2%, 95% CI 0-4%; I(2) = 76.34%) compared to retrospective studies (0%, 95% CI 0-1%; I(2) = 91.51%). Male predominance was noted among patients who experienced seizures, and hypertension was the most common comorbidity. Cerebral hyperperfusion syndrome was identified as a key contributing factor to postoperative seizures. Data on long-term outcomes, including the development of epilepsy, were insufficient for further analysis. The methodological quality of the included studies varied, with most studies demonstrating a moderate risk of bias. Conclusions: Seizures occur in approximately 1% of patients following CEA, with higher rates observed in prospective studies. Cerebral hyperperfusion syndrome is an important contributor to this rare complication. We provide evidence-based specific recommendations for seizure management and introduce the SMART-CEA Checklist, a practical framework to guide perioperative care and reduce complications. Future research should focus on long-term outcomes, including epilepsy, and incorporate standardized methodologies to improve data reliability and guide clinical practice.

Access full text

6. The risk factors of postoperative cognitive dysfunction in patients undergoing carotid endarterectomy: an updated meta-analysis

Authors: He, Jinhua; Duan, Ran; Qiu, Peng, et al
Publication Date: 2023
Journal: Journal of Cardiothoracic Surgery 18(1), pp.309–6

Abstract: OBJECTIVE: The purpose of the current meta-analysis was to determine the incidence and risk factors to provide a scientific basis for prevention and treatment of postoperative cognitive dysfunction (POCD) after carotid endarterectomy (CEA). METHODS: Relevant articles published before October 2022 were searched from Pubmed/MEDLINE, Cochrane and Embase databases. The outcomes were the incidence and risk factors for POCD. A random-effects model was applied to estimate the overall odds ratios (ORs) and mean differences (MDs) for all risk factors through STATA 14.0 and RevMan 5.4. The quality of eligible studies was evaluated by Newcastle-Ottawa Scale (NOS) as previously described. RESULTS: A total of 22 articles involving 3459 CEA patients were finally identified. The weighted mean incidence of POCD was 19% (95% confidence intervals (95% CI) 0.16-0.24, P < 0.001). Of the 16 identified risk factors, hyperperfusion (OR: 0.54, 95% CI 0.41-0.71) and degree of internal carotid artery (ICA) stenosis (OR: 5.06, 95% CI 0.86-9.27) were the potential risk factors of POCD, whereas patients taking statins preoperative had a lower risk of POCD (OR: 0.54, 95% CI 0.41-0.71). Subgroup analysis revealed that the risk of POCD at 1 month after CEA was higher in patients with diabetes (OR: 1.70, 95% CI 1.07-2.71). CONCLUSION: The risk factors of POCD were hyperperfusion and degree of ICA stenosis, while diabetes could significantly increase the incidence of POCD at 1 month after surgery. Additionally, preoperative statin use could be a protective factor for POCD following CEA.

Access full text 

7. Neurocritical Care Aspects of Ischemic Stroke Management

Authors: Qaryouti, Dania and Greene-Chandos, Diana
Publication Date: 2023
Journal: Critical Care Clinics 39(1), pp.55–70

Abstract: This article reviews the care of patients with ischemic stroke in the intensive care unit, including early general critical care interventions for airway control blood pressure goals according to the type of acute stroke treatment, poststroke cerebral edema management, hemorrhagic conversion in ischemic stroke, fibrinolytic reversal, and management of carotid endarterectomy and infective endocarditis. The importance of preventing common intensive care complications is discussed, including aspiration pneumonia, deep venous thrombosis, urinary tract infections, cardiac arrhythmias, and hyperglycemia.

Access full text

8. Improving Quality of Carotid Interventions: Identifying Hospital-Level Structural Factors that can Improve Outcomes

Authors: Gaba, Kamran; Morris, Dylan; Halliday, Alison, et al
Publication Date: 2021
Journal: Annals of Vascular Surgery 72, pp.589–600

Abstract: BACKGROUND: “Structural factors” relating to organization of hospitals may affect procedural outcomes. This study’s aim was to clarify associations between structural factors and outcomes after carotid endarterectomy (CEA) and carotid endarterectomy stenting (CAS). METHODS: A systematic review of studies published in English since 2005 was conducted. Structural factors assessed were as follows: population size served by the vascular department; number of hospital beds; availability of dedicated vascular beds; established clinical pathways; surgical intensive care unit (SICU) size; and specialty of surgeon/interventionalist. Primary outcomes were as follows: mortality; stroke; cardiac complications; length of hospital stay (LOS); and cost. RESULTS: There were 11 studies (n = 95,100 patients) included in this systematic review. For CEA, reduced mortality (P 75,000 people. Larger hospitals were associated with lower mortality, stroke rate, and cardiac events, compared with smaller hospitals (less than 130 beds). Provision of vascular beds after CEA was associated with lower mortality (P = 0.0008) and fewer cardiac events (P = 0.03). Adherence to established clinical pathways was associated with reduced stroke and cardiac event rates while reducing CEA costs. Large SICUs (≥7 beds) and dedicated intensivists were associated with decreased mortality after CEA while a large SICU was associated with reduced stroke rate (P = 0.001). Vascular surgeons performing CEA were associated with lower stroke rates and shorter LOS (P = 0.0001) than other specialists. CAS outcomes were not influenced by specialty but costless when performed by vascular surgeons (P < 0.0001). CONCLUSIONS: Structural factors affect CEA outcomes, but data on CAS were limited. These findings may inform reconfiguration of vascular services, reducing risks and costs associated with carotid interventions.

Access full text

Posted in Ward Round Update | Leave a comment

Temperature control in patients with traumatic brain injury

Following ward round on 10 September, please find below some further reading on temperature control in patients with traumatic brain injury.

Please note that inclusion in this blog is not an endorsement of quality.

Please follow local protocols for drug doses.

To access full text you will need an NHS OpenAthens account. Please sign up here if you haven’t already got one.

KnowledgeShare is a current awareness tool which helps you deal with information overload, while ensuring that you receive high quality information on topics that are important to you. Take five minutes to fill in this form and we will send you regular updates on your chosen topic.

Guidance

ESICM/NACCS (2024) Targeted temperature control following traumatic brain injury: ESICM/NACCS best practice consensus recommendations

Articles

1. Temperature control in acute brain injury

Authors: Lavinio, Andrea; Busl, Katharina M.; Coles, Jonathan P., et al
Publication Date: 2026
Journal: Intensive Care Medicine 52(4), pp.714–728

Abstract: PURPOSE: Temperature is a key determinant of cerebral vulnerability after acute brain injury and a physiological variable that can be continuously monitored and actively controlled in the intensive care unit. Its therapeutic role has evolved from hypothermia-centred strategies toward early recognition of fever and controlled normothermia. This review examines the physiological rationale, clinical evidence, and contemporary practice of temperature management in neurocritical care. METHODS: We synthesised evidence from major randomised trials, observational studies, and international consensus recommendations across traumatic brain injury, acute vascular brain injury, and post-cardiac arrest encephalopathy, together with current monitoring and implementation approaches. RESULTS: Fever is consistently associated with worse neurological outcomes. In traumatic brain injury, hypothermia reduces intracranial pressure but does not improve functional outcome when used prophylactically and is reserved for refractory intracranial hypertension. In acute vascular brain injury, neutral trials and feasibility constraints have shifted practice toward early detection and treatment of fever rather than hypothermia. In post-cardiac arrest care, contemporary guidelines recommend protocolised temperature control with selection and maintenance of a constant target between 32°C and 37.5°C and active prevention of fever, rather than mandatory hypothermia. CONCLUSIONS: Temperature control is a fundamental component of care aimed at protecting the injured brain through continuous monitoring, early detection of fever, and prevention of temperature-related harm.

Access full text

2. Review of Temperature Management in Traumatic Brain Injuries

Authors: Kawakita, Kenya; Shishido, Hajime and Kuroda, Yasuhiro
Publication Date: 2024
Journal: Journal of Clinical Medicine 13(7), pp.2144. doi: 10.3390/jcm13072144

Abstract: Therapeutic hypothermia (TH) for severe traumatic brain injury has seen restricted application due to the outcomes of randomized controlled trials (RCTs) conducted since 2000. In contrast with earlier RCTs, recent trials have implemented active normothermia management in control groups, ensuring comparable intensities of non-temperature-related therapeutic interventions, such as neurointensive care. This change in approach may be a contributing factor to the inability to establish the efficacy of TH. Currently, an active temperature management method using temperature control devices is termed “targeted temperature management (TTM)”. One of the goals of TTM for severe traumatic brain injury is the regulation of increased intracranial pressure, employing TTM as a methodology for intracranial pressure management. Additionally, fever in traumatic brain injury has been acknowledged as contributing to poor prognosis, underscoring the importance of proactively preventing fever. TTM is also employed for the preemptive prevention of fever in severe traumatic brain injury. As an integral component of current neurointensive care, it is crucial to precisely delineate the targets of TTM and to potentially apply them in the treatment of severe traumatic brain injury.

Access full text

3. Temperature Control in Acute Brain Injury: An Update

Authors: Lin, Victor; Tian, Cindy; Wahlster, Sarah, et al
Publication Date: 2024
Journal: Seminars in Neurology 44(3), pp.308–323

Abstract: Temperature control in severe acute brain injury (SABI) is a key component of acute management. This manuscript delves into the complex role of temperature management in SABI, encompassing conditions like traumatic brain injury (TBI), acute ischemic stroke (AIS), intracerebral hemorrhage (ICH), aneurysmal subarachnoid hemorrhage (aSAH), and hypoxemic/ischemic brain injury following cardiac arrest. Fever is a common complication in SABI and is linked to worse neurological outcomes due to increased inflammatory responses and intracranial pressure (ICP). Temperature management, particularly hypothermic temperature control (HTC), appears to mitigate these adverse effects primarily by reducing cerebral metabolic demand and dampening inflammatory pathways. However, the effectiveness of HTC varies across different SABI conditions. In the context of post-cardiac arrest, the impact of HTC on neurological outcomes has shown inconsistent results. In cases of TBI, HTC seems promising for reducing ICP, but its influence on long-term outcomes remains uncertain. For AIS, clinical trials have yet to conclusively demonstrate the benefits of HTC, despite encouraging preclinical evidence. This variability in efficacy is also observed in ICH, aSAH, bacterial meningitis, and status epilepticus. In pediatric and neonatal populations, while HTC shows significant benefits in hypoxic-ischemic encephalopathy, its effectiveness in other brain injuries is mixed. Although the theoretical basis for employing temperature control, especially HTC, is strong, the clinical outcomes differ among various SABI subtypes. The current consensus indicates that fever prevention is beneficial across the board, but the application and effectiveness of HTC are more nuanced, underscoring the need for further research to establish optimal temperature management strategies. Here we provide an overview of the clinical evidence surrounding the use of temperature control in various types of SABI.

Request full text

4. Therapeutic Hypothermia Compared with Normothermia in Adults with Traumatic Brain Injury; Functional Outcome, Mortality, and Adverse Effects: A Systematic Review and Meta-Analysis

Authors: Martyniuk, Amanda; Hart, Shannon; Lannon, Melissa, et al
Publication Date: 2024
Journal: Neurocritical Care 41(2), pp.400–417

Abstract: BACKGROUND: The main focus of traumatic brain injury (TBI) management is prevention of secondary injury. Therapeutic hypothermia (TH), the induction of a targeted low core body temperature, has been explored as a potential neuroprotectant in TBI. The aim of this article is to synthesize the available clinical data comparing the use of TH with the use of normothermia in TBI. METHODS: A systematic search was conducted through MEDLINE, EMBASE, and Cochrane Central Register of Controlled Trials for randomized clinical trials including one or more outcome of interest associated with TH use in TBI. Independent reviewers evaluated quality of the studies and extracted data on patients with TBI undergoing TH treatment compared with those undergoing normothermia treatment. Pooled estimates, confidence intervals (CIs), and risk ratios (RRs) or odds ratios were calculated for all outcomes. RESULTS: A total of 3,909 patients from 32 studies were eligible for analysis. Pooled analysis revealed a significant benefit of TH on mortality and functional outcome (RR 0.81, 95% CI 0.68-0.96, I(2) = 41%; and RR 0.77; 95% CI 0.67-0.88, I(2) = 68%, respectively). However, subgroup analysis based on risk of bias showed that only studies with a high risk of bias maintained this benefit. When divided by cooling method, reduced poor functional outcome was seen in the systemic surface cooling and cranial cooling groups (RR 0.68, 95% CI 0.59-0.79, I(2) = 35%; and RR 0.44, 95% CI 0.29-0.67, I(2) = 0%), and no difference was seen for the systemic intravenous or gastric cooling group. Reduced mortality was only seen in the systemic surface cooling group (RR 0.63, 95% CI 0.53-0.75, I(2) = 0%,); however, this group had mostly high risk of bias studies. TH had an increased rate of pneumonia (RR 1.24, 95% CI 1.10-1.40, I(2) = 32%), coagulation abnormalities (RR 1.63, 95% CI 1.09-2.44, I(2) = 55%), and cardiac arrhythmias (RR 1.78, 95% CI 1.05-3.01, I(2) = 21%). Once separated by low and high risk of bias, we saw no difference in these complications in the groups with low risk of bias. Overall quality of the evidence was moderate for mortality, functional outcome, and pneumonia and was low for coagulation abnormalities and cardiac arrhythmias. CONCLUSIONS: With the addition of several recent randomized clinical trials and a thorough quality assessment, we have provided an updated systematic review and meta-analysis that concludes that TH does not show any benefit over normothermia in terms of mortality and functional outcome.

Access full text

5. Targeted temperature management and P(bt)O(2) in traumatic brain injury

Authors: Cujkevic-Plecko, Nika; Rodriguez, A.; Anderson, T., et al
Publication Date: 2023
Journal: Brain & Spine 3, pp.102704

Abstract: INTRODUCTION: Targeted Temperature Management (TTM) to normothermia is widely used in traumatic brain injury (TBI). We investigated the effects to of TTM to normothermia patients with TBI (GCS≤12) monitored with multimodality monitoring, to better understand the physiological consequences of this intervention. RESEARCH QUESTION: In TBI patients cooled to normothermia and in which brain oxygenation deteriorates, are there changes in physiological parameters which are pertinent to brain oxygenation? MATERIAL AND METHOD: 102 TBI patients with continuous recordings of intracranial pressure (ICP) and brain oxygen tension (P(bt)O(2)) were studied retrospectively. Non-continuous arterial carbon dioxide (P(a)CO(2)) and oxygen (P(a)O(2)) tensions, and core body temperature (T(c)) were added. P(a)O(2) and P(a)CO(2) were also corrected for T(c). Transitions from elevated T(c) to normothermia were identified in 39 patients. The 8 h pre and post the transition to normothermia were compared. Data is given as median [IQR] or mean (SD). RESULTS: Overall, normothermia reduced ICP (12 [9-18] -11 [8-17] mmHg, p < 0.009) and T(core) (38.3 [0.3]-36.9 [0.4] (o)C, p < 0.001), but not P(bt)O(2) (23.3 [16.6]-24.4 [17.2-28.7] mmHg, NS). Normothermia was associated with a fall in P(bt)O(2) in 18 patients (24.5 [9.3] -20.8 [7.6] mmHg). Only in those with a fall in P(bt)O(2) with cooling did ICP (15 [10.8-18.5] -12 [7.8-17.3] mmHg, p = 0.002), and temperature corrected P(a)CO(2) (5.3 [0.5]- 4.9 [0.8] kPa, p = 0.001) decrease. DISCUSSION AND CONCLUSION: A reduction in P(bt)O(2) was only present in the subgroup of patients with a fall in temperature corrected P(a)CO(2) with cooling. This suggests that even modest temperature changes could result in occult hyperventilation in some patients. pH stat correction of ventilation may be an important factor to consider in future TTM protocols.

Access full text

6. Overview of Hypothermia, Its Role in Neuroprotection, and the Application of Prophylactic Hypothermia in Traumatic Brain Injury

Authors: Trieu, Christine; Rajagopalan, Suman; Kofke, W. Andrew, et al
Publication Date: 2023
Journal: Anesthesia and Analgesia 137(5), pp.953–962

Abstract: The current standard of practice is to maintain normothermia in traumatic brain injury (TBI) patients despite the theoretical benefits of hypothermia and numerous animal studies with promising results. While targeted temperature management or induced hypothermia to support neurological function is recommended for a select patient population postcardiac arrest, similar guidelines have not been instituted for TBI. In this review, we will examine the pathophysiology of TBI and discuss the benefits and risks of induced hypothermia in this patient population. In addition, we provide an overview of the largest randomized controlled trials testing-induced hypothermia. Our literature review on hypothermia returned a myriad of studies and trials, many of which have inconclusive results. The aim of this review was to recognize the effects of hypothermia, summarize the latest trials, address the inconsistencies, and discuss future directions for the study of hypothermia in TBI.

Request full text

Posted in Ward Round Update | Leave a comment

Devastating brain injury

Following ward round on 28 July, please find below some further reading on devastating brain injury pathways and prognostication.

Please note that inclusion in this blog is not an endorsement of quality.

Please follow local protocols for drug doses.

To access full text you will need an NHS OpenAthens account. Please sign up here if you haven’t already got one.

KnowledgeShare is a current awareness tool which helps you deal with information overload, while ensuring that you receive high quality information on topics that are important to you. Take five minutes to fill in this form and we will send you regular updates on your chosen topic.

UK guidance

Intensive Care Society (2018) Devastating Brain Injury Consensus-Statement

Articles

1. Impact of a Devastating Brain Injury Pathway on Outcomes, Resources, and Organ Donation: 3 Years’ Experience in a Regional Neurosciences ICU

Authors: Rivers, Jon; Manara, Alex R.; Thomas, Ian, et al
Publication Date: 2020
Journal: Neurocritical Care 33(1), pp.165–172

Abstract: OBJECTIVE: To assess the impact of introducing a devastating brain injury (DBI) pathway on patient outcome, intensive care unit (ICU) resources, and organ donation practice in the first 3 years of implementation in a regional neurosciences ICU in the South West of England. METHODS: Patients with DBI admitted to our ICU between 2015 and 2018 were identified from our ICU database and their outcomes compared to those of non-DBI patients. Data were also obtained from the national potential donor audit to compare organ donation metrics before and after the introduction of the DBI pathway. Organ donation metrics in DBI patients and non-DBI patients were compared once the pathway had been implemented. RESULTS: We admitted 85 DBI patients (1.3% of all admissions), with a significantly shorter median length of ICU stay than in non-DBI patients, 1.14 versus 2.93 days (p < 0.001). Decisions for withdraw life-sustaining treatments (WLST) were made significantly earlier in DBI patients, median 26.2 versus 84.8 h (p < 0.001). Over 8% of DBI patients survived, while 31% progressed to brain death compared to 7.1% in the general population (p < 0.001), and 25% become solid organ donors compared to 1.3% of the general population (p < 0.001). There was an increase in the proportion of donors after brain death (DBD) to donors after circulatory death (DCD) in the 3 years following the introduction of the DBI pathway (p = 0.024). There was also an increased proportion of DBD donors to DCD donors of 76% versus 24% in the DBI group compared to 62% versus 38% (p = 0,002) in the non-DBI population. Prognostic scoring systems do not provide accurate estimates of survival rate in this population. CONCLUSIONS: Admitting patients with perceived DBI to ICU and avoiding the early WLST allows identification of unexpected survivors and gives families more time in decision making at the end of life. The DBI pathway increases the potential for organ donation and increases the proportion of DBD donors. These benefits outweigh the small impact of a DBI pathway on ICU resources.

Access full text: https://libkey.io/10.1007/s12028-019-00879-1

2. Outcomes of the first full year of implementing a devastating brain injury pathway

Authors: Manara, Alex R. and Thomas, Ian
Publication Date: 2017
Journal: Journal of the Intensive Care Society 18(1), pp.83

Abstract: not available. This is an update on outcomes of the article below (Manara 2016).

Access full text: https://libkey.io/10.1177/1751143716670410

3. A case for stopping the early withdrawal of life sustaining therapies in patients with devastating brain injuries

Authors: Manara, Alex R.; Thomas, Ian and Harding, Richard
Publication Date: 2016
Journal: Journal of the Intensive Care Society 17(4), pp.295–301

Abstract: Early prognostication in patients with a devastating brain injury is not always accurate and can lead to inappropriate decisions. We present case histories to support the recent recommendations of the Neurocritical Care Society that treatment withdrawal decisions should be delayed by up to 72 h in these patients. Development of pathways incorporating these recommendations can improve prognostication, enhance end of life care given to these patients and their families, and increase the opportunities to explore the donation wishes of more patients. They may also standardise the approach to decision making in the same way as the recommendations for management of patients after out of hospital cardiac arrest have done.

Access full text: https://libkey.io/10.1177/1751143716647980

4. Recommendations for the Critical Care Management of Devastating Brain Injury: Prognostication, Psychosocial, and Ethical Management : A Position Statement for Healthcare Professionals from the Neurocritical Care Society

Authors: Souter, Michael J.; Blissitt, Patricia A.; Blosser, Sandralee, et al
Publication Date: 2015
Journal: Neurocritical Care 23(1), pp.4–13

Abstract: Devastating brain injuries (DBIs) profoundly damage cerebral function and frequently cause death. DBI survivors admitted to critical care will suffer both intracranial and extracranial effects from their brain injury. The indicators of quality care in DBI are not completely defined, and despite best efforts many patients will not survive, although others may have better outcomes than originally anticipated. Inaccuracies in prognostication can result in premature termination of life support, thereby biasing outcomes research and creating a self-fulfilling cycle where the predicted course is almost invariably dismal. Because of the potential complexities and controversies involved in the management of devastating brain injury, the Neurocritical Care Society organized a panel of expert clinicians from neurocritical care, neuroanesthesia, neurology, neurosurgery, emergency medicine, nursing, and pharmacy to develop an evidence-based guideline with practice recommendations. The panel intends for this guideline to be used by critical care physicians, neurologists, emergency physicians, and other health professionals, with specific emphasis on management during the first 72-h post-injury. Following an extensive literature review, the panel used the GRADE methodology to evaluate the robustness of the data. They made actionable recommendations based on the quality of evidence, as well as on considerations of risk: benefit ratios, cost, and user preference. The panel generated recommendations regarding prognostication, psychosocial issues, and ethical considerations.

Access full text: https://libkey.io/10.1007/s12028-015-0137-6

Posted in Ward Round Update | Leave a comment